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Abstract 
Anatomical and tumour changes can occur during chemoradiotherapy for 
head and neck cancer (HNC).  These include changes in weight, primary 
tumour or nodal disease size and post-operative responses such as oedema.  
This has been highlighted with the discovery of virally associated HNC that 
undergo dramatic changes during a treatment course.  Anatomical and 
tumour changes are of particular importance with the routine use of intensity 
modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) 
and Tomotherapy.  These techniques enable delivery of high radiation doses 
to tumour volumes whilst minimising dose to surrounding structures with 
resultant reduction in toxicities.  This is achieved through the creation of very 
steep dose gradients between structures.  The steep dose gradients created 
allow very little tolerance for variation meaning that changes that occur over 
a treatment course can lead to potential under-dosing or geographic miss of 
the tumour and may limit the benefits associated with these highly conformal 
techniques.  This problem needs to be considered and addressed when 
developing appropriate treatment approaches.   
 
Adaptive radiotherapy (ART) has been evaluated to assess its effectiveness 
in addressing the anatomical changes that can occur during treatment 
resulting in the need to re-plan.  However, the ART process can be 
demanding on departmental resources with re-planning procedures requiring 
both additional use of planning equipment and staff time.  Consequently, it is 
imperative that patients who are likely to require ART are correctly identified 
as early as possible in the treatment process.  This will facilitate the effective 
implementation of ART into radiotherapy (RT) departments by forward 
planning, resulting in gains in efficiency and appropriate allocation of 
departmental resources.  Currently, there is limited understanding of the 
factors that could predict the need for ART prior to the commencement of 
treatment.  As such, the aim of this research was to investigate a predictive 
approach to ART for HNC. 
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As part of developing a predictive algorithm, a retrospective review of 
patients with virally associated HNC was conducted to determine factors that 
may assist with predicting the need for ART.  The dosimetric impact of 
anatomical changes was also investigated to establish which structures were 
most affected by these changes.  It was found that the pre-treatment size of 
the largest involved node was a significant factor in predicting the need for 
ART.  Specifically, those patients with virally associated HNC and a pre-
treatment nodal size of ≥ 46 mm appeared to be a high-risk group that were 
more likely to be re-planned during a course of definitive RT.  Treatment-
induced anatomical changes were found to have the greatest impact on 
organs at risk (OAR) dose (spinal cord, brainstem, parotid glands) with 
negligible effect on the dose to nodal gross tumour volumes.  
 
The findings from this study were investigated in a prospective setting 
encompassing HNC patients with and without virally associated disease.  
The aim of this study was to develop a predictive model and associated risk 
profiles for clinical implementation, identifying patients more likely to require 
ART.  Nodal disease stage, pre-treatment largest involved node size, 
diagnosis and initial weight (categorised in 2 groups) were identified as 
significant for inclusion in the model.  Three ART risk profiles (high, 
intermediate and low) were developed based on the predictive model. 
 
Optimal timing of adaptive intervention was also assessed in order to 
develop a comprehensive ART strategy for these patients.  It was found that 
the median time of re-imaging was significantly different between patients 
who were re-planned and those that were not, with re-planned patients being 
re-imaged earlier: median fraction 18 versus fraction 23.  Specifically, 
nasopharyngeal carcinoma (NPC) patients who were re-planned were re-
imaged earlier than oropharyngeal cancer (OPC) patients (median fraction 
11 versus 20).  
 
This work has developed a predictive approach to HNC ART that can be 
clinically implemented.  This facilitates a pre-emptive response to the 
anatomical and tumour changes that HNC patients can experience during 
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treatment promoting improved patient outcomes and enhanced utilisation of 
departmental resources. 
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Background!
• HNC patients experience considerable anatomical change during 
definitive or post-operative chemoradiotherapy  
• Potential detrimental impact on dose distribution resulting in under or 
over dosing of tumour and surrounding critical structures   
• ART addresses problem by adjusting RT plan in accordance with 
anatomical changes  
• Process is time and resource intensive 
 
!
Overall!objective!
Prospectively identify oropharyngeal and nasopharyngeal carcinoma patients 
receiving RT treatment that will benefit from ART 
 
!
Primary!endpoints!
1.  Identify predictive factors for patients more likely to require re-planning 
2.  Develop risk profiles and ART treatment management strategies for HNC 
patients 
 
!
Methods!
1.   Retrospective study to identify potential predictive factors and develop        
preliminary risk profiles 
a.  Dosimetric investigation to determine structures most impacted 
2.  Prospective study to test and refine predictive factors and risk profiles 
a.  Daily monitoring of patients to determine optimal timing of ART 
 
!
Conclusion!
• Risk profiles developed to predict HNC patients more likely to require 
ART 
• Complementary treatment management strategy indicates optimal 
timing of ART and during-treatment monitoring approaches   
• Enables departments to adopt forward planning approach to ART 
resulting in efficiency gains and appropriate resource allocation !
! 19!
Chapter 1 Introduction 
Considerable advancements have been made in the area of head and neck 
cancer (HNC) radiotherapy (RT) treatment techniques in the last decade.  
Techniques such as intensity modulated radiotherapy (IMRT), volumetric arc 
modulated arc therapy (VMAT) and Tomotherapy enable high doses to be 
delivered to tumour volumes while minimising the dose delivered to 
surrounding healthy tissues through the creation of very steep dose 
gradients.  This results in more efficacious treatment and a reduction in side 
effects.[1]  Patients undergoing RT for HNC can experience anatomical and 
tumour changes during a seven week course of treatment.  These changes 
have the potential to negatively impact the original treatment plan.[2]  
Adaptive radiotherapy (ART) is an approach to correct for these changes via 
modification of the treatment plan.[3]  The aim of this project was to 
investigate a predictive approach to ART for HNC. 
1.1 Research problem 
Chemoradiotherapy is integral in the treatment of locally advanced head and 
neck squamous cell carcinoma.[4]  Patients can experience significant side 
effects including well documented anatomical and tumour changes that 
become obvious over the six to seven week period of RT.  These may occur 
as a result of treatment related toxicities or response of the tumour itself to 
treatment.  Common responses include weight loss and tumour or node 
volume changes and post-operative consequences such as inflammation 
and oedema.[5, 6]  
 
The RT dose distribution is calculated on a computed tomography (CT) scan 
performed at a planning session conducted prior to the commencement of 
treatment.  This CT scan is only representative of the patient’s anatomy at 
that particular moment in time and will not reflect any changes that occur to 
that patient over the course of treatment.  Consequently, the resultant impact 
of any such change on the originally planned radiation dose distribution will 
not be demonstrated.  This is particularly pertinent in the current context 
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where highly conformal radiotherapy such as IMRT, VMAT and Tomotherapy 
are the gold standard techniques for HNC.[7, 8]  The primary characteristic of 
these techniques is their ability to create steep dose gradients between 
tumour volumes and surrounding critical and healthy tissues.[9]  This results 
in tumour volumes being treated to high prescription doses while dose to the 
surrounding healthy tissues and subsequent side effects are minimised.[10]  
Patient and tumour changes have the potential to disturb this balance and 
can result in target volumes receiving inadequate dose and the dose 
delivered to surrounding critical structures and healthy tissues exceeding 
prescribed tolerances.[11]  This may have a bearing on patient outcomes 
and its implications can vary depending on the magnitude of the impact on 
the dose distribution.[2]  Inadequate coverage of the tumour volume by the 
prescribed dose could potentially lead to loco-regional recurrence.[5]  
Exceeding the tolerance dose of critical structures can result in an array of 
side effects as well as an increase in their severity.  These side effects can 
range from myelopathy and blindness to dysphagia and xerostomia.[12-15]      
 
This issue has increased importance in the current HNC environment where 
the traditional patient demographic is shifting.  While the association between 
nasopharyngeal carcinoma (NPC) and the Epstien Barr Virus (EBV) has long 
been established, the association between oropharyngeal carcinoma (OPC) 
and the human papillomavirus (HPV) has more recently emerged.[13, 16, 17]  
It has been reported that virally associated cancers consist of 45-90% of 
OPC and NPC.[18, 19]  In contrast to the classic HNC patient presentation, 
these patients tend to be younger, commonly have advanced nodal disease, 
have limited exposure to alcohol and tobacco and respond well to 
radiotherapy.[18, 20]  Patients with virally associated disease have been 
shown to have an improved prognosis in comparison to those that do 
not.[21]  This means that patients are living longer with the side effects of 
treatment, such as dysphagia and xerostomia, making it essential to address 
this issue. 
 
ART is an effective method of addressing the dosimetric impact of 
anatomical and tumour change.  ART in this context is defined as the 
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modification of the original radiation treatment plan during a course of 
radiotherapy to account for temporal changes in the patient’s anatomy.[1]  
The utilisation of ART can maintain adequate tumour volume coverage by 
the prescribed dose and reduce surrounding critical structure dose, leading 
to improved quality of life for patients.[22]  Despite obvious benefits, 
implementation of ART can be challenging for departments as it is a very 
time and resource intensive process and may result in increased financial 
burden.[5, 23]  This is due to the increased workload for Radiation 
Oncologists, Radiation Therapists and Medical Physicists associated with re-
imaging, re-contouring and re-planning.[11]  Consequently, being able to 
accurately predict those patients that may require ART during treatment is of 
vital importance for optimal efficiency and best practice patient care in!RT 
departments. 
1.2 Overall study aim 
The overall aim of this study was to prospectively identify OPC and NPC 
patients that will be likely to require ART during RT treatment. 
1.3 Specific objectives of the study 
1. Identify patient and tumour characteristics that predispose a patient to 
requiring ART during their treatment course (Chapters 4 and 6) 
2. Develop a predictive model and risk profiles based on this information 
to enable departments to adopt a forward planning approach to ART 
through appropriate allocation of departmental resources (Chapter 6) 
3. Identify optimal timing for scheduling of re-imaging during treatment, 
for re-planning purposes, for inclusion in a comprehensive predictive 
ART strategy (Chapter 7) 
4. Determine the dosimetric impact of anatomical and tumour change on 
planned dosimetry using highly conformal techniques (i.e. IMRT, 
VMAT and Tomotherapy) in the Australian setting (Chapters 5 and 6) 
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1.4 Significance to Radiation Therapy 
It is widely acknowledged that ART is time and resource intensive and is 
associated with increased departmental financial burdens.[5, 24]  These 
practical and logistic challenges are barriers to the more widespread 
inclusion of ART both in Australia and internationally.  Consequently, the 
identification of patients most likely to require ART is key to ensuring it is 
utilised for those patients that will benefit most.  In light of this, many authors 
have recognised the need to determine factors that predict patients who are 
most likely to require ART in order that departmental resources are allocated 
and utilised appropriately.  This study aims to address this identified need by 
using both retrospective and prospective studies to determine predictive 
factors and validate them, and thus contribute to the literature in this area. 
1.5 Account of research process linking the papers 
In order to develop a predictive approach to the ART process for HNC 
patients, it was necessary to evaluate patients who were identified for 
adaptive intervention using the previous ‘ad hoc’, reactive approach.  
  
1. Chapter 4 describes the retrospective study to determine the 
magnitude of virally associated HNC patients that were undergoing some 
type of adaptive intervention during treatment and then identify common 
characteristics amongst this group.  The primary aim of this study was to 
develop potential risk profiles and associated adaptive management 
strategies that would be most effective for these patients.  The preliminary 
risk profiles identified in Chapter 4 were refined in the prospective study 
described in Chapter 6. 
 
An important element of forming the prospective study to refine these 
preliminary risk profiles was the identification of surrounding critical 
structures that would be most impacted dosimetrically by anatomical and 
tumour change.   
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2. The aim of Chapter 5 was to evaluate the dosimetric effect of 
treatment-induced anatomical changes in virally associated HNC patients 
who had undergone a re-plan.  Evaluation of the dosimetric impact and 
identification of structures most affected by change enabled these structures 
to be focused upon in the prospective study.  It also provided a baseline for 
comparison of the dosimetric impact between the older treatment techniques 
used in the retrospective study and the current gold standard technique used 
in the prospective study. 
 
The preliminary risk profiles and results of the studies conducted in Chapters 
4 and 5 provided the foundation of the prospective study undertaken in 
Chapter 6.   
 
3. The primary aim of this chapter was to find predictive factors that 
identify OPC and NPC patients more likely to need ART in a controlled 
setting.  These factors were used to develop logistic regression models and 
predictive risk profiles which can be easily implemented in the clinical setting 
to prospectively identify HNC patients who are pre-disposed to being 
selected for ART.  This enables RT departments to employ a forward 
planning approach to HNC ART facilitating the appropriate allocation of 
resources. 
 
4. Chapter 7 extends the predictive HNC ART approach to form a 
comprehensive strategy.  A key element of predictive HNC ART is the timing 
of re-planning.  This is of importance, because if the timing of the re-planning 
process can be scheduled before a patient commences treatment, a more 
seamless workflow for Radiation Oncologists, Radiation Therapists and 
Medical Physicists will result.  The aim of Chapter 7 was to facilitate a 
forward planning ART approach by identifying the pre-treatment factors that 
influence the need for and timing of re-planning for patients receiving 
chemoradiotherapy for node-positive NPC and OPC.  The development of 
this well-rounded HNC ART approach may also encourage the more 
widespread adoption of this technique in RT centres.   
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5. Considerable variation was found in the reported percentage of 
patients that undergo reimaging and replanning in H&N ART literature.  
Chapter 8 therefore, examined the reasons for this disparity to place the 
results described in Chapters 6 and 7 in an international context.  This was 
important to demonstrate the applicability of the findings, because if 
international replanning rates are higher, the results of the current work will 
greatly assist in the systematic evaluation of the need of ART for H&N 
cancer patients.  
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Chapter 2 Literature Review 
RT treatment is integral in the management of locally advanced HNC, either 
as adjuvant or definitive therapy.  RT can take a significant toll on the patient, 
the results of which are visible during a treatment course.  Side effects 
experienced by patients during treatment include oral mucositis, dysphagia 
and changes in taste1.  The result of these side effects, combined with 
treatment-related tumour response, can result in considerable anatomical 
change and have a major impact on the planned dose distribution leading to 
additional patient toxicity2-5. 
 
The association between NPC and EBV and OPC and HPV has been well 
established6-9.  It has been reported that approximately 70% of OPC in 
western countries are HPV positive7.  These tumours have an intrinsic 
sensitivity to radiation treatment and consequently respond well to radiation 
therapy10-14 as demonstrated in Figure 2. 1.  These patients typically 
experience a complete response and are long-term survivors7.  As a result, 
patients live longer with debilitating post treatment functional side effects as 
will be discussed further in this chapter1.  Therefore, it is important that the 
issue of potential additional patient toxicity as a result of anatomical change 
during treatment is addressed.  ART is one strategy that can be employed to 
minimise the detrimental effects of anatomical changes during treatment.   
 
This literature review will discuss the effect of RT on HNC to explore the 
need for specific adaptive radiation treatment strategies.  It will examine the 
relationship between HPV and EBV, OPC and NPC, the effect of RT on HNC 
and various aspects of ART treatment strategies that could be employed to 
improve outcomes for these patients.   
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Figure 2. 1  Radiotherapy treatment response of HPV positive 
oropharyngeal cancer patient with advanced nodal disease. Note the 
difference in the patient’s external contour between the planning CT (outlined 
in red) and a CT scan taken 4 weeks into treatment.  
Image courtesy of PAH Radiation Oncology Department. 
2.1 Historical background 
2.1.1 Radiation therapy treatment in head and neck cancer 
High rates of disease control can be achieved using gold standard 
chemoradiotherapy treatment regimes for patients with HNC, allowing them 
to avoid the morbidities and long-term quality of life (QoL) issues associated 
with radical surgical resection15, 16.   Highly conformal, modulated techniques, 
such as IMRT and VMAT are now employed as the RT technique of choice 
for HNC17-20.  These techniques employ modulation to create steep dose 
gradients between structures.  The clinical manifestation of these 
improvements has been demonstrated through a reduction in toxicities 
experienced by patients21.  However, geometric and anatomical changes that 
can occur over a treatment course may limit the benefits associated with 
these highly conformal techniques due to the steep dose gradient that occurs 
over millimetres.  As such this should be considered when developing 
appropriate treatment approaches for these patients22. 
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2.1.2 EBV and HPV in head and neck cancer 
There has been a steady increase in the incidence of certain types of HNC, 
particularly OPC, over the past few decades 15,23.  The most common risk 
factors for HNC, excessive tobacco and alcohol exposure, do not correlate 
with the rise in incidence14,24.  Clinical data has produced compelling 
evidence that confirms the role of viruses in this subset of HNC patients 
(Figure 2. 2)15,25,26.   
 
!
Figure 2. 2  Incidence rate for overall oropharyngeal cancer, human 
papillomavirus (HPV)-positive oropharyngeal cancers and HPV-negative 
oropharyngeal cancers during 1988 to 2004 in Hawaii, Iowa and Los Angeles 
(Chaturvedi et al 2011)23 
HPVs are a family of small DNA viruses that infect epithelial cells of the skin 
and mucosa11. Infection with a HPV primarily results in primarily benign, self-
limiting warts or in epithelial tumours, as in the case of OPC11.  EBV is an 
agent with growth transforming potential for!human!B cells and is associated 
with certain!B cell lymphomas!and undifferentiated!NPC27. 
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The link between EBV and NPC was first recognised in 1966 and formally 
identified in 19706.  This association has been found to be constant, 
regardless of other patient characteristics6.  It has been reported that certain 
strains of EBV may be associated with a higher risk of NPC but as yet, there 
is no definitive evidence6. 
 
The aetiological role of HPV in OPC cancer has been clearly established 
over the past two decades1,15.  Most HPV-related oropharyngeal cancers are 
caused by one virus type, HPV 1612.  Recently, two HPV vaccines have 
become widely available.  The bivalent and quadrivalent vaccines protect 
against infection with HPV types 16 and 18 and types 6, 11, 16 and 18 
respectively28.  The efficacy of these vaccines to prevent non-cervical HPV-
related cancers is yet to be assessed28. 
 
The impact of HPV on patient characteristics, clinical presentation, 
histopathology and prognosis of OPC patients has been confirmed in a 
number of studies9,10.  In a meta-analysis on patient survival of squamous 
cell carcinoma HNC in relation to HPV infection29, Ragin and Taioli noted 
that while most studies reported an improvement in prognosis, several 
studies reported no difference or worse outcome.  In contrast, Marur et al.12 
report that for OPC, HPV-positive patients had a significantly (p<0.0001) 
better prognosis in comparison with HPV-negative patients.  This finding has 
also been substantiated in other studies13,15,26,30 and as a consequence, viral 
association must be taken into consideration in HNC-related clinical trials31.  
!
Improvement in prognosis for virally associated HNC patients has been 
linked to increased sensitivity to radiation therapy treatment7,8,12,32.  A meta-
analysis investigating the outcome of HPV-positive OPC discovered that 
these patients have a better overall disease specific survival and progression 
free survival than those with HPV-negative disease33.  As all of these 
patients had RT as part of their treatment regime, the hypothesis that HPV-
positive OPC are more radiosensitive than HPV-negative OPC was 
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confirmed33.  The specific mechanism behind the increased response of 
virally associated HNC to radiation therapy treatment remains unclear.  It has 
been proposed that it may be attributable to the presence and oncogenesis 
of specific viral proteins11, 26.  The combination of radiation and 
chemotherapeutic agents may also decrease the capacity of HPV E6/E7 to 
interfere with p53 or pRb proteins increasing the susceptibility of these 
cancers to treatment33.  This increase in radiosensitivity and improved 
prognosis warrants further investigation to determine specific and unique 
treatment strategies for patients with virally associated HNC. 
2.2 Organ at Risk (OAR) dose and functional 
relationships in HNC 
There are a number of critical and QoL organs at risk (OAR) located in the 
head and neck region.  Critical OAR include the spinal cord, brainstem and 
brachial plexus and QoL OAR include the parotid glands, pharyngeal 
constrictors and larynx.  As previously mentioned, side effects related to 
irradiation of these organs, such as xerostomia, dysphagia, changes in taste, 
aspiration and fibrosis, can be debilitating and have a significant impact on 
QoL34.  Highly conformal RT techniques, such as IMRT improve the 
therapeutic ratio20.  The therapeutic ratio aims to optimise the balance 
between maximising the damage inflicted on tumour cells whilst minimising 
injury to surrounding normal, healthy tissue.  However, this means that even 
slight anatomical changes, such as tissue loss related to tumour regression, 
can upset this balance and have major impact on OAR doses and thus 
patient QoL causing irreversible damage to organs such as the spinal cord 
and parotid glands35, 36, 37, 38.  Additional OAR anatomical changes that occur 
are notable volume shrinkage during treatment, resulting in increased dose 
being received by these organs39, 40. 
 
Xerostomia, or dry mouth, is the most frequently occurring side effect during 
and after RT for HNC and is caused by radiation-induced damage to the 
salivary glands, particularly the parotid glands41.  Loss of functionality of the 
parotid glands can have a major impact on a patient’s QoL, both in the short 
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and long term.  Its effect on patient QoL has been observed in physical, role 
and social functioning as well as fatigue and insomnia36.  IMRT has 
facilitated the limitation of dose to the parotid glands, enabling retention of at 
least partial functionality post treatment41.  However, many studies have 
demonstrated a decrease in parotid gland volume and a medial shift in their 
position during a course of radiation treatment, resulting in an increase in the 
delivered radiation dose compared with the planned dose3,35.  This has 
prompted investigation into techniques that can be employed during 
treatment to ensure that OAR receive the dose that was originally planned42. 
2.3 Adaptive radiation therapy in HNC 
Tumours in the head and neck region can be subject to significant 
anatomical changes during RT treatment potentially altering the planned 
radiation dose distribution43,44.  Changes can ultimately lead to suboptimal 
radiation dose distributions45-47.  This is demonstrated in Figure 2. 3 where 
there is an increase in the dose received by the spinal cord as a result of 
weight loss and tumour regression that has occurred during treatment.  The 
clinical consequences of suboptimal radiation dose distribution include an 
increased potential risk of tumour recurrence, and complications3.  This has 
implications for treatment success rates, acute and long-term toxicities and 
overall patient QoL.   
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Figure 2. 3  (a) Radiotherapy treatment plan demonstrating the planned 
dose distribution (b) Dose distribution after 24 fractions of treatment showing 
an increase in spinal cord dose due to weight loss and tumour shrinkage 
(Ahn et al, 2011)20 
 
ART techniques have been evaluated to assess their effectiveness in 
addressing this important issue20,32,38.  In this context, ART is defined as an 
approach to correct for tumour and normal tissue variations that occur 
throughout treatment via modification of the treatment plan48.  A crucial tool 
that has enabled the successful employment of ART is image guided 
radiotherapy (IGRT).  IGRT is the use of in-room imaging devices, for 
example kilovoltage or megavoltage cone beam CT (CBCT, MVCT), planar 
imaging and ultrasound, to assess both positional and anatomical variation49.  
The use of soft tissue, volumetric IGRT is prevalent throughout the literature 
in studies investigating ART50-52.  This enables changes that occur to a 
patient to be monitored and quantified on a daily basis to determine the need 
for treatment plan modification.  
 
ART techniques are potentially very important to patients with virally 
associated OPC and NPC due to their unique presentation and 
characteristics.  These techniques can optimise their treatment strategies by 
maintaining the integrity of the original RT treatment plan, despite the 
occurrence of anatomical changes, and minimising post treatment side 
effects. 
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2.4 Predictive risk factors for adaptive intervention 
The ART process can be resource intensive on a department with the re-
planning procedure requiring both additional use of planning equipment and 
staff time.  Furthermore, re-planning needs to occur in a contracted 
timeframe, adding increased pressure.  The identification of predictive factors 
specific to these patients is an important component of achieving this and is 
an issue that requires further study50,54.  Investigation of various external 
predictors for the need to re-plan including skin separation and positional 
variation found no single anatomical or positional variable was a reliable 
predictor20 54.  In contrast, Capelle and colleagues assessment of ART in 
HNC patients treated with helical tomotherapy found that the degree of 
weight loss and reduction in neck separation were reliable predictive factors 
that offered the greatest benefit from adaptive intervention55.  Evidenced by 
the disparity and paucity of results reported in literature, there is still 
considerable research that needs to be conducted in this area.  Additionally, 
the majority of potential predictive factors and selection criteria reported have 
been based on the use of correlation tests when, as Brouwer and colleagues 
comment53, regression analyses are more suited to investigating predictive 
power.  This is due to the ability of regression analyses to predict variable 
weightings as opposed to only describing the relationship between factors as 
is the case with correlation tests.   
 
To date, the majority of studies have only investigated factors that predict the 
need for adaptive intervention whilst the patient is on treatment.  There is 
little published data on identifying characteristics prior to the commencement 
of a patient’s treatment that could predict the need for a re-plan during the 
course of treatment.  Elective scheduling of adaptive re-planning prior to the 
commencement of RT treatment has been reported to be of benefit for NPC 
patients55.  However, no similar recommendations were made for other HNC 
patients55.  In Surucu et al’s. study to develop decision making trees to 
predict tumour shrinkage in head and neck squamous cell carcinoma 
(HNSCC), chemotherapy, age, primary tumour growth pattern, site, 
Karnofsky performance status (KPS) and HPV status were identified as 
! 36!
being predictive parameters for percentage primary gross tumour volume 
(GTV) change56.  The study also reported that KPS, site, age, primary 
tumour growth pattern, initial primary GTV and total GTV volumes were 
predictive factors for percentage nodal GTV change56.  Identification of 
predictive factors for ART prior to the commencement of treatment would 
facilitate a more pre-emptive and streamlined departmental workflow and 
warrants further investigation. 
2.5 Optimal timing and frequency of plan adaption 
The optimal timing of plan adaption is a balance between waiting sufficient 
time from the commencement of treatment for clinically significant anatomical 
change to occur whilst having enough treatment time remaining for the 
adaptive plan to have a clinically meaningful impact on the radiation dose 
distribution.  The frequency of re-planning can have a considerable impact 
on departmental resources.  The literature provides little consensus on either 
optimal timing or frequency of plan adaption.  A study conducted by Bhide et 
al. found that the majority of anatomical change had occurred by week 2 of 
treatment and therefore recommended that this was the time point at which 
adaptive re-planning should occur35.  In contrast another study reported that 
week 3 of treatment was the optimum time to intervene as this is the time by 
which the parotid glands have undergone the greatest amount of change19.  
In terms of re-planning frequency and its dependency on re-planning criteria, 
it has been found that the more precise the planned dose is required to be 
maintained over the course of treatment, the more frequently re-planning is 
required57. Schwartz and colleagues found that in their cohort of 22 patients, 
all patients required at least one re-plan and 36% of patients required 2 re-
plans58.  Therefore it still remains unclear what cost, time and effort is 
appropriate in clinical routine with regards to ART. 
 
Rate and magnitude of anatomical change are key factors in determination of 
optimal timing and frequency of adaptive re-planning.  This may even differ 
between cancer diagnoses due to differing rates of tumour regression and 
weight loss and is worthy of further investigation particularly in relation to 
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virally associated HNC59, 60.  A crucial tool in the successful employment of 
ART is IGRT, particularly in investigating the rate and magnitude of 
anatomical change.  Studies have also found that IGRT such as cone beam 
CT provide sufficient information to predict dosimetric deviations in most 
cases61,62.  In recent times the use of IGRT has been coupled with 
deformable image registration techniques to assist in monitoring volumetric 
changes that have occurred and streamlining the adaptive process63.  These 
newer technologies will further support the successful implementation of ART 
into clinical practice as they become more widely commercially available in 
the future.  
2.6 Selection criteria for re-planning 
In general, the selection criteria used in current published studies to trigger a 
re-plan have been poorly defined and patients have been selected for 
adaptive intervention based upon the discretion of the treating Radiation 
Oncologist51.  Adding to the problem is the dynamic and varied way in which 
HNC patients respond to treatment.  Ahn and colleagues20 found that 65% of 
patients studied benefited from ART due to decreased OAR dose and/or 
improved PTV coverage.  In contrast, Ho and colleagues62 reported no 
benefit from adaptive re-planning.  The differences between these studies 
can be attributed to: differences in cohort size, re-planning frequency and 
that the study by Ho and colleagues involved re-planning calculations being 
performed using CBCT.   
 
Similarly, variation in terms of the dosimetric impact of anatomic change on 
OAR has been reported.  Studies conducted by Wu et al.38, Zhang et al.64 
and Jin et al.18 found no significant difference between planned and 
delivered doses for the spinal cord and brainstem.  A significant increase in 
delivered dose to the parotid glands was reported and re-planning was 
recommended in specific patients to reduce this.  In contrast, studies 
conducted by Hansen et al.44 and Zhao et al.32 found that anatomical 
changes during treatment significantly increased dose to surrounding OAR 
such as the spinal cord and brainstem.  Multiple factors may contribute to 
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this dosimetric variability including the differing time points at which the plan 
recalculation was performed, relative locations of the target volumes and 
OAR and variable beam arrangements and dose gradients.  These findings 
highlight the need to incorporate an individualised approach when 
developing HNC ART guidelines. 
 
Although many studies have suggested improvement of tumour volume 
coverage when ART is employed, there are many and varied factors that 
ultimately contribute to the decision to re-plan including: patient condition and 
clinical considerations, initial dose distribution and variation for tumour 
volumes and OAR as well as available departmental resources54.  The 
decision to re-plan involves the critical assessment of the patient in terms of 
the improvement in plan quality that can be achieved.  Currently there are no 
clear guidelines that exist to provide a benchmark by which a clinical 
decision can be made61.  Tanyi and colleagues make the observation that 
the clinical impact of continued dose delivery using the original plan in such 
cases that may require re-planning is not captured61.  It is unknown whether 
these dosimetric changes would translate to decreased rates of loco-regional 
control or increased rates of normal tissue complications61.  Numerous 
studies indicate the need to better identify reproducible ‘triggers’ or clear 
dosimetric criteria that can serve to better inform the decision to re-plan32,51,54.  
This is important not only to identify those patients that will benefit from re-
planning but also to minimise the number of patients that undergo 
rescanning for the purpose of re-planning unnecessarily.   
2.7 Summary and implications 
Although chemoradiotherapy remains the mainstay of HNC cancer treatment, 
there are many other factors that have and continue to change in HNC.  RT 
techniques are becoming increasingly conformal, facilitating the delivery of 
high doses to tumour volumes while further minimising the dose to 
surrounding healthy, normal tissues.  Additionally, the landscape of HNC 
aetiology has altered with the discovery of viral associations, giving rise to 
further investigation into its impact on treatment regimes and patient 
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outcomes.  Alongside this progress is the long-standing knowledge that HNC 
cancer patients can experience a considerable amount of anatomical change 
during a course of definitive chemoradiotherapy treatment potentially 
resulting in detrimental impact to the patient’s planned dose distribution. ART 
is one possible solution to address this.  The body of knowledge in this area 
is continually expanding however, review of the literature reveals that further 
investigation into specific ART strategies is required to determine targeted 
guidelines and criteria for their implementation in all HNC patients, including 
radioresponsive tumours such as virally associated OPC and NPC 3,44,48.   
 
The purpose of this research is to prospectively identify HNC patients 
undergoing chemoradiotherapy treatment that will benefit most from ART.  
Predictive risk factors will be determined and these factors incorporated into 
a predictive model.  This model can be employed clinically to prospectively 
schedule adaptive intervention, re-CT and re-plan, in the patient’s treatment 
prior to their commencement.  It is also imperative that evidence-based ART 
guidelines accompany this predictive model to enable appropriate resource 
allocation in a department.  This should include guidelines on the optimal 
timing and frequency of adaptive intervention and clear selection criteria to 
inform the decision to re-plan.  The use of IGRT must form a central part of 
this investigation due to its ability to provide three-dimensional information 
regarding the changes occurring in the patient during the course of treatment.  
Detailed, daily image information will provide helpful insight into the patients 
in which changes occur in addition to the timing and magnitude of these 
changes.  This, coupled with clear and consistent guidelines on when re-
imaging for the purposes of re-plan assessment is to occur, will provide a 
firm foundation on which development of these guidelines can be undertaken. 
This should provide departments with an effective ART model that can be 
easily implemented and ultimately lead to the improvement of HNC patient 
outcomes and QoL, particularly those with virally associated disease. 
   !  
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Chapter 3 Research Design 
 
This research study was designed to investigate the development of a 
balanced, predictive approach to adaptive radiotherapy (ART) for head and 
neck cancer (HNC) patients.  In order to develop this approach, the following 
research questions were raised: 
 
Q1: How does oropharyngeal cancer (OPC) and nasopharyngeal cancer 
(NPC), particularly those that are virally associated, respond to 
radiation therapy? 
 
Q2: What is the resultant impact of anatomical variation on the 
radiotherapy plan dose distribution, specifically dose to target volumes 
and OAR? 
 
Q3: Are there factors that can predict the probability of a patient with 
OPC or NPC being selected for ART? 
 
Q4: What is the optimal timing of adaptive intervention? 
 
The primary objective of this research was to identify patient and tumour 
characteristics that predispose a patient with OPC or NPC to requiring ART.  
A predictive model and risk profiles were developed based on these factors.  
The secondary objective was to identify the optimal timing for scheduling of 
re-imaging during treatment for the purpose of re-planning. 
 
To achieve these objectives, a two-phase approach was adopted as outlined 
in Figure 3. 1.  Conducting both retrospective and prospective phases was 
necessary to properly address this topic.  Firstly, it enabled an appreciation 
of the extent to which ART was required and potential influential factors to be 
gained.  Subsequently, this knowledge could be applied and refined in a 
more controlled setting.  A two-phase approach also allowed feedback to be 
sought on the project after the completion of the first phase, through the 
! 48!
submission of journal articles, and these comments incorporated into the 
second phase of the study. 
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Q1: How does OPC and NPC, particularly those that are virally 
associated, respond to radiation therapy treatment? 
 
Q2: What is the resultant impact of anatomical variation on the 
radiotherapy plan dose distribution, specifically dose to target volumes 
and OAR? 
 
Q3: Are there factors that can predict the probability of a patient with 
OPC or NPC being selected for ART? !
Activity – Phase 1 (Chapters 4 and 5) 
Retrospective cohort study 
• Review HNC patient treatment journeys 
• Determine magnitude of patients requiring ART 
• Identify common factors amongst re-planned patients 
• Assess dosimetric impact on target volumes and OAR of 
anatomical variation 
• Develop preliminary ART risk profiles 
Q3: Are there factors that can predict the probability of a patient with 
OPC or NPC being selected for ART? !
Q4: What is the optimal timing of adaptive intervention? 
 
Q2: What is the resultant impact of anatomical variation on the 
radiotherapy plan dose distribution, specifically dose to target volumes 
and OAR? !
Objectives:  
Identify patient and tumour characteristics that predispose a patient to 
requiring ART during their treatment course 
Determine the dosimetric impact of anatomical and tumour change on 
planned dosimetry 
 
Objectives: 
Identify patient and tumour characteristics that predispose a patient to 
requiring ART and develop a predictive model and risk profiles 
Identify optimal timing for scheduling of re-imaging during treatment 
Activity – Phase 2 (Chapters 6 and 7) 
Prospective cohort study 
• Compare demographic and tumour factors for patients 
who were re-planned vs. no re-planning 
• Identify common factors amongst re-planned patients and 
refine preliminary risk profiles 
• Review timing of adaptive intervention to determine 
optimal timing of ART 
• Assess dosimetric impact on target volumes and OAR of 
anatomical variation to develop clinical guidelines 
•  
Figure 3. 1  Outline of research design 
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3.1 Objectives 
Identify patient and tumour characteristics that predispose a patient to 
requiring ART during their treatment course 
Determine the dosimetric impact of anatomical and tumour change on 
planned dosimetry 
 
The associated research questions were: 
1: How does OPC and NPC, particularly those that are virally associated, 
respond to radiation therapy treatment? 
2: What is the resultant impact of anatomical variation on the radiotherapy 
plan dose distribution, specifically dose to target volumes and OAR? 
3: Are there factors that can predict the probability of a patient with OPC or 
NPC being selected for ART? 
 
The methodology used to address these first research questions was a 
single centre retrospective cohort study of patients with virally associated 
OPC or NPC.  Eligible patient treatment journeys were analysed to 
determine whether adaptive intervention occurred and the timing of this 
intervention.  Dosimetric impact of anatomical variation on target volume 
coverage and OAR dose was also assessed.  Statistical testing aided in 
developing preliminary risk profiles to be tested in Phase 2 of the study. 
 
Statistical analysis 
For the patients reviewed in this phase, the number and magnitude of 
adaptive planning interventions that occurred were identified as well as 
factors that may contribute to the need for patients to undergo a re-CT or re-
plan. Statistical analysis included basic descriptive statistics and logistic 
regression analysis to determine the predictive value of the developed risk 
profiles. Classification and regression tree (CART) analysis was used to 
determine the relative contribution of factors such as initial weight, nodal size, 
and disease stage to the need for adaptive intervention.  In the regression 
analyses, a p-value of <0.05 was considered statistically significant. Risk 
profiles were determined based on the nodal sizes of patients who 
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underwent adaptive interventions in comparison to those who did not.  The 
sample size for Phase 2 of this study was based on further analysis of the 
relationships found between the need for re-planning and various patient and 
tumour characteristics. 
 
The research schema for the Phase 1 retrospective cohort study is 
demonstrated in Figure 3. 2. 
 
The publications describing the results of this phase of the study form 
Chapters 4 and 5 of this thesis. 
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Identification of patients with oropharyngeal and NPC head and 
neck cancer treated with curative EBRT between 2005-2010 
Inclusion criteria: 
• HPV positive OPC 
• EBV positive NPC 
• Node positive 
• Curative intent (Radiation prescription of 66Gy or 
higher) 
n = 121 !
Record patient demographics, tumour characteristics (including 
nodal size) and treatment plan/prescription and sort into disease 
specific groups (NPC or oropharyngeal) !
Retrieve treatment plan, assess treatment plan delivered !
Re-CT performed? !
Yes ! No !
1. What was the reason for the re-CT and/or re-plan? 
• Obvious tumour and/or nodal regression 
• Weight loss (assessed visually and with weight loss percentage) 
• Both 
• Other 
2. When did the re-CT occur? !
Re-planning required? !
Yes ! No !
Comparison of re-plan vs. no re-plan: 
• Dosimetric effect on tumour and nodal volumes 
• Dosimetric effect on organs at risk 
o Spinal cord 
o Brainstem 
o Lt and Rt Parotids !
Development of risk profiles for adaptive radiation therapy treatment 
management strategy 
• Low risk 
• Intermediate risk 
• High risk !
Figure 3. 2  Phase 1 research schema 
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3.2 Objectives 
Identify patient and tumour characteristics that predispose a patient to 
being selected for ART and develop a predictive model and risk profiles 
Identify optimal timing for scheduling of re-imaging during treatment 
 
The associated research questions were: 
1: Are there factors that can predict the probability of a patient with OPC or 
NPC being selected for ART? 
2: What is the optimal timing of adaptive intervention? 
3: What is the resultant impact of anatomical variation on the radiotherapy 
plan dose distribution, specifically dose to target volumes and OAR? 
 
The methodology used to address these research questions was a multi 
centre prospective cohort study of patients with OPC or NPC.  The 
preliminary risk profiles developed in Phase 1 were used to categorise 
patients determining whether a re-CT was prospectively scheduled (high risk 
group) and when detailed review of daily volumetric treatment imaging 
should occur (intermediate group).  Eligible patient demographics and 
tumour factors were compared between patients who were re-planned and 
those that were not to identify common factors amongst re-planned patients 
and refine the preliminary risk profiles.  Timing of adaptive intervention was 
reviewed to determine the optimal timing of ART.  The impact of anatomical 
variation on target volume and OAR dose was recorded, specifically for the 
spinal cord, brainstem and parotid glands.  However, the dosimetric impact 
to other critical OAR, such as the brachial plexus and optic structures, was 
monitored as part of the re-planning process in those patients where high 
dose target volumes were in close proximity to these structures. 
 
Statistical analysis 
From the results of Phase 1, it was determined that a sample size of 107 
patients was required for logistic regression analysis looking at the following 
variables: pre-treatment dominant nodal size, initial patient weight and age.  
Regression analysis demonstrated a relationship between pre-treatment 
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dominant node size (p-value <0.001), age (p-value 0.07) and initial weight (p-
value 0.05) with one outlier removed (R-squared 0.83, Adjusted R-squared 
0.805).  A sample size of 133 patients was required to include disease stage 
in the logistic regression analysis.   
 
Patients who were re-planned were compared with those that did not to 
identify common characteristics among the re-plan group.  A three-stage 
approach was taken to the statistical analyses.  For the first step, univariate 
and multivariate analyses were used including Chi squared and Mann-
Whitney tests to compare various factors between the groups.  Comparison 
of dosimetric factors was conducted between the original treatment plan and 
the delivered dose using the Wilcoxon matched-pairs signed-ranks test.  
These tests were used as the data was not normally distributed.  Tested 
factors included gender, age, diagnosis, disease stage, viral status, initial 
weight and initial size of the pre-treatment dominant node.  A p-value of ≤ 
0.05 was considered statistically significant.  For the second stage logistic 
regression was used to model the relationship between the categorical 
outcome and explanatory variables. The explanatory variables used were 
determined in stage one.  Logistic regression was used as the outcome 
being investigated was binary (i.e. re-plan).  In the regression analyses, the 
binary response variable was the requirement for a re-plan and a p-value of 
p ≤ 0.05 was considered to be statistically significant.  For the third stage, 
CART were used to identify interacting relationships between explanatory 
variables and the categorical response variable. Only the identified 
explanatory variables were included in the CART analysis.  The results of 
these analyses were used to refine the preliminary risk profiles.  
 
Further analyses was conducted on patients who underwent re-imaging.  
Univariate and multivariate analyses were used to compare patients whose 
re-CT resulted in the generation of a re-plan with those that did not.  Mann-
Whitney tests were used to compare various factors between patients who 
were re-planned and those who were not as the data were not normally 
distributed.  Tested factors included the fraction the re-CT was performed, 
diagnosis, weight at planning and at re-CT and size of the largest involved 
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node at planning and at re-CT.  Bonferroni correction was used when 
appropriate to adjust for multiple testing.  Logistic regression was used to 
model the relationship between the requirement for a re-plan and the 
explanatory variables found to be significant in univariate analysis.  
Comparison of dosimetric factors was conducted between the original 
treatment plan and the delivered dose using the Wilcoxon matched-pairs 
signed-ranks test.  Mann-Whitney tests were also used to compare delivered 
doses between patients who had a re-plan generated and those that did not.  
A p-value of ≤ 0.05 was considered statistically significant.  The results of 
these analyses were used to further develop the ART management strategy. 
 
The research schema for the Phase 2 prospective cohort study is 
demonstrated in Figure 3. 3. 
 
The publications describing the results of this phase of the study form 
Chapters 6 and 7 of this thesis. 
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Identification of eligible patients 
Inclusion criteria: 
• Informed consent 
• Oropharyngeal ca 
• Nasopharyngeal ca 
• Node positive 
• Curative intent (Radiation prescription of 
66Gy or higher) 
n = 107 
Determination of adaptive treatment strategy as assessed 
using risk profiles developed in Phase A !
Low risk 
Minimal (<10%) need 
for adaptive RT 
• N0 nodal status 
• Dominant pre-
treatment nodal 
size ≤ 35mm !
Intermediate risk 
Possible (<20%) need for adaptive 
RT 
• Dominant pre-treatment 
nodal size 36mm – 45mm 
• If spinal cord or parotid 
glands within 5% of 
tolerance dose !
High risk 
High likelihood (>50%) 
to need adaptive RT 
• Dominant pre-
treatment nodal 
size ≥ 46mm 
Analysis of all patient plans and treatment journeys for all risk profiles to test adaptive treatment 
management strategy 
• Assessment of each risk profile 
o All patients have daily CBCTs to assess tumour and/or nodal regression, weight loss 
o CBCTs of patients in intermediate and high risk groups to be specifically monitored by 
senior staff weekly 
o Correlation between CBCT and planning re-CT (pre-booked at nominal date #15) 
! Whether pre-booked planning re-CT was required 
! Timing 
o Dosimetric comparison between initial treatment plan and re-plan 
Confirmation and/or refinement of risk profiles and adaptive treatment management 
strategy !
Figure 3. 3  Phase 2 research schema 
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Chapter 4 
The purpose of this study was to develop preliminary risk profiles for HNC 
ART, the first objective of this research.  This study was a retrospective 
review of patients with virally mediated head and neck cancer (VMHNC).  It 
was undertaken to assess the characteristics of patients who respond well 
during a radiotherapy treatment course to identify specific predictive factors 
that could determine which patients will benefit most from ART.  This 
information is valuable in forming the basis of a standardised approach to 
pre-emptively manage this group to ensure benefit to the patient and optimal 
use of departmental resources.   
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ABSTRACT 
Purpose 
Virally mediated head and neck cancers (VMHNC) often present with nodal 
involvement and are highly radioresponsive, meaning that treatment plan 
adaptation during radiotherapy (RT) in a subset of patients is required. We 
sought to determine potential risk profiles and a corresponding adaptive 
treatment strategy for these patients. 
  
Methodology 
121 patients with virally mediated, node positive nasopharyngeal (Epstein 
Barr Virus positive) or oropharyngeal (Human Papillomavirus positive) 
cancers, receiving curative intent RT were reviewed.  The type, frequency 
and timing of adaptive interventions, including source-to-skin distance (SSD) 
corrections, re-scanning and re-planning, were evaluated.  Patients were 
reviewed based on the maximum size of the dominant node to assess the 
need for plan adaptation.  
 
Results 
Forty-six patients (38%) required plan adaptation during treatment.  The 
median fraction at which the adaptive intervention occurred was 26 for SSD 
corrections and 22 for re-planning CTs.   A trend toward 3 risk profile 
groupings was discovered: 1) Low risk with minimal need (< 10%) for 
adaptive intervention (dominant pre-treatment nodal size of 35 mm), 2) 
Intermediate risk with possible need (< 20%) for adaptive intervention 
(dominant pre-treatment nodal size of 36 mm – 45 mm) and 3) High-risk with 
increased likelihood (> 50%) for adaptive intervention (dominant pre-
treatment nodal size of 	 46 mm). 
  
Conclusion 
In this study, patients with VMHNC and a maximum dominant nodal size of ≥ 
46 mm were identified at a higher risk of requiring re-planning during a 
course of definitive RT.  Findings will be tested in a future prospective 
adaptive RT study.    
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Introduction 
Clinical investigation over the past 2 decades has produced an increased 
recognition of the etiological links between particular viruses and certain 
head and neck cancers. The association between nasopharyngeal cancer 
(NPC) and increased expression of the Epstein Barr Virus (EBV) has long 
been established [1].  Recent studies have demonstrated a causal 
association between oropharyngeal squamous cell carcinoma (OSCC) and 
infection with the Human Papillomavirus (HPV), particularly the p16 strain of 
the virus [2, 3].  These VMHNC’s collectively represent a subset of cancers 
with a distinct clinical entity [4]. Compared with traditional head and neck 
cancers, they generally have greater likelihood of response to therapy, are 
not necessarily related to smoking, have a more favourable prognosis and 
have a different pathway of malignant transformation [5].  For this reason the 
investigators agreed that it would be appropriate to study both virally 
mediated NPC and OSCC.  As many of these patients are long-term 
survivors, reducing the burden of treatment-related toxicity is paramount.  
This can be achieved by further minimizing the dose delivered to surrounding 
functional healthy tissue.  Adaptive radiotherapy (RT) is one strategy to 
reduce treatment-related acute and long-term toxicity. 
 
Adaptive RT is an approach to correct for various geometric variations that 
occur during a patient’s treatment [6].  It includes repeated image-based 
modification of treatment delivery and the adjustment of the treatment plan to 
account for changes in the patient’s anatomy during the treatment period [2, 
3].  Anatomical changes include primary tumour and/or nodal shrinkage and 
weight loss [7]. Techniques such as intensity modulated radiotherapy (IMRT) 
highlight the importance of adaptive planning due to the potential impact 
induced by anatomical changes on these highly conformal dose distributions 
with steep dose gradients [6].  
 
Methodology for dealing with treatment-induced anatomical changes has 
typically relied on the clinical judgment of the treating Radiation Therapists.  
To date, no standardized indicator for asymmetric anatomical changes exists 
which adds to the difficulty of streamlined treatment adaptation.  
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This study is a retrospective review of patients with virally mediated head 
and neck cancer (VMHNC), who attended the Princess Alexandra Hospital 
(PAH) for definitive RT between 2005 and 2010.  It was undertaken to 
assess the characteristics of patients who respond well during a radiotherapy 
treatment course to identify specific predictive factors that could determine 
which patients will benefit most from adaptive RT.  This information is 
valuable in forming the basis of a standardized approach to pre-emptively 
manage this group to ensure benefit to the patient and optimal use of 
departmental resources.  The primary aim was to develop potential risk 
profiles and associated adaptive management strategies that would be most 
effective for these patients. It was hypothesized that the need for adaptive 
intervention is related to the dominant nodal size at diagnosis.  
 
Methods and Materials 
Patients 
Patients with VMHNC who received definitive RT treatment with or without 
systemic therapy, between 2005 and 2010 were identified from a prospective 
head and neck PAH database and retrospectively reviewed.  Eligibility 
criteria included: histologically confirmed NPC or OSCC, with either positive 
serology for EBV or p16 (immunostaining >70%) and node positive disease 
with any T stage disease and treatment plan accessible on the treatment 
planning system.  Patient demographics and tumour characteristics 
(including pre-treatment size of the dominant node) were recorded.  Nodal 
size data was collected from each patient’s diagnosis and staging 
information.  Treatment technique was also recorded as both three-
dimensional conformal radiotherapy (3DCRT) and IMRT was used during the 
study period.  The project was approved by the Human Research Ethics 
Committees from the Princess Alexandra Hospital and Queensland 
University of Technology (3rd June, 2011).!!
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Assessment of adaptive planning interventions 
Treatment techniques employed and associated image guidance protocols 
evolved over the study period.  It incorporated both 3DCRT with weekly 
electronic portal imaging and IMRT with weekly cone beam computed 
tomography (CBCT) imaging.  CBCT replaced the practice of taking manual 
separations to assess treatment response.  There was no protocol to identify 
patients requiring adaptive planning interventions or guidelines on what 
adaptive planning intervention to employ.  Decisions were made based on 
the treating Radiation Therapists’ judgement on a daily basis.  However, if 
there was a change in body contour outline, separation or source-to-skin 
distance (SSD) reading of greater than 1cm, the plan was returned to 
planning for review for the duration of the study.   
 
The adaptive planning interventions used at this time were categorised as 1) 
SSD correction or monitor unit (MU) adjustment as a result of changes in 
SSD readings, 2) Re-CT or performing a second planning computed 
tomography scan and 3) Re-plan or generation of another treatment plan 
based on the re-CT scan.  Details of the above 3 interventions, including 
timing, affected fields, magnitude of change as well as weight and volume 
changes, were recorded. 
 
SSD corrections 
SSD corrections are a planning intervention used in the department to adapt 
the daily dose delivered by a field to match treatment-induced changes in the 
patient’s separation. These are defined as an adjustment to a field’s planned 
MUs based on either a change in the daily treatment SSD from the planned 
SSD, or a change in the separation recorded at the time of treatment from 
the planned separation.  Relevant standard separation points (reference 
point and minimum spinal cord separation) were identified for each patient 
and used for assessment of that patient throughout treatment.  This MU 
adjustment was calculated using a specially designed, in-house program.  
Table 1 shows the input information required for each affected field.  An SSD 
correction was only applied to fields that had a change in SSD during 
treatment.   
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The dose and fraction at which the separation change occurred as well as 
the difference between the planned and treatment measurements at the 
reference point and minimum spinal cord separation was recorded.  The 
design of the calculation program employed by the department at the time of 
the study meant that corrections were applied to 3DCRT techniques only and 
not IMRT techniques. 
 
Table 1 Information required for SSD correction calculation 
Data field 
Beam energy 
Equivalent square field size 
Planned MU 
Planned path length from surface to isocentre at reference point 
New path length from surface to isocentre at reference point# 
Number of fractions change applicable for 
Number of remaining fractions  
# Determined by difference in separation measurement from planning or 
planned SSD from average treatment SSD since change occurred. 
 
Re-CT 
Re-CT was defined as any patient that underwent a second planning CT to 
assess anatomical changes during their treatment course.  This did not 
include cone beam CTs (CBCT) taken on the treatment unit itself.  A re-CT 
was requested based on the clinical judgment of the radiation oncologist or 
treating Radiation Therapists.  A re-CT indicated that the treating Radiation 
Therapists considered the patient’s response to treatment had the potential 
to impact upon the treatment plan and warranted further investigation.  It may 
or may not have resulted in an actual adjustment to the treatment. 
 
For those patients that underwent a re-CT, the time, dose and fraction were 
recorded.  If a plan adaption was indicated, no standard protocol existed as 
to whether an SSD correction or re-CT was performed.  The reason for the 
re-CT was evaluated in consultation with the treating radiation oncologist by 
reviewing an image registration of the planning CT scan and the re-CT scan 
on the treatment planning system.  This image registration was performed 
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using bony anatomy minimising the influence of daily set up variation.  The 
reason for the re-CT was categorised into: 1) primary tumour volume 
regression based on the contoured GTV, 2) nodal volume regression, 3) 
weight loss or a combination of these factors.  Patients who underwent a re-
CT were further investigated and other contributing factors including 
magnitude of weight loss, primary tumour volume regression, nodal tumour 
volume regression and whether a new RT plan was generated were 
recorded.   
 
Re-plan 
A re-plan involves the generation of a new RT plan calculated on the re-CT 
data, accounting for treatment-induced anatomical changes.  The original 
target volumes may have been re-contoured based on the radiation 
oncologist’s observation of the repeat CT scan registered with the planning 
CT scan.  This meant that the re-plan might have used either the original 
beam arrangement or an altered approach.  A verification plan was created 
for IMRT patients where the planned fluence map and MU were applied to 
the re-CT.  If a re-plan was performed, the dosimetric effect was quantified 
by comparing dose volume histograms (DVH) derived from the treatment 
delivered and the original treatment plan of gross target volumes (primary 
and nodal tumour volumes) and critical structures.  This comparison allowed 
the effect of re-planning or adaptive treatment management to be evaluated.  
 
Statistics 
Data was analysed using the Stata (version 12.1, StataCorp LP, Texas, 
USA) program. The number and magnitude of adaptive planning 
interventions were identified as well as factors that may contribute to the 
need for patients to undergo a re-CT and/or re-plan.  Statistical analysis 
included basic descriptive statistics and logistic regression analysis to 
determine the predictive value of the risk profiles.  Classification and 
regression tree (CART) analysis was used to determine the relative 
contribution of factors such as initial weight, nodal size and disease stage to 
the need for adaptive intervention.  In the regression analyses, a p-value of < 
0.05 was considered statistically significant.  Risk profiles were determined 
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based on the nodal sizes of patients who underwent adaptive interventions in 
comparison to those that did not.    
 
Results 
Patient characteristics 
122 patients out of 221 met the inclusion criteria.  Of the 122 patients 
identified, one patient was excluded due to missing treatment information.  
The characteristics of the 121 eligible patients can be seen in Table 2.  
Patients were predominantly male, 105 patients had HPV-positive OSCC 
and 16 had EBV-positive NPC cancer.  Forty-six (38%) patients required 
varying types of plan adaptation during treatment:  32 (26.4%) had an SSD 
correction, 25 (20.7%) a re-CT and 16 (13.2%) a re-plan.  43.5% of patients 
underwent multiple adaptive interventions with 4 patients undergoing both a 
re-CT and SSD correction and 7 patients undergoing a re-plan and SSD 
correction.  One patient was excluded from the dominant nodal size analysis 
as it was considered an extreme case (150mm) and was greater than 4 
standard deviations outside the mean.  Table 3 shows a comparison of 
patient characteristics for patients requiring a planning intervention and those 
who had no intervention.  Of the 121 patients, 8 were treated with an IMRT 
technique with the remaining patients treated with 3DCRT.   
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Table 2 Patient characteristics 
 
  Characteristics 
Sex  
Male 106 
Female 15 
Age mean (range) 54 (22-81) 
Primary tumour site  
Tonsil 65 
Base of tongue 34 
Other 6 
Nasopharynx 16 
T classification  
0 2 
1 26 
2 38 
3 34 
4 21 
N classification  
1 12 
2 93 
3 16 
Smoking history  
Never 39 
Former 49 
Active 33 
Nodal size mean (range) 37.1mm (13mm-150mm) 
Oropharynx 36.6mm (13mm-150mm) 
Nasopharynx 40.3mm (14mm-90mm) 
Treatment technique  
3DCRT 113 
IMRT 8 
Planning intervention 46 
SSD correction 32 
Oropharynx 25 
Nasopharynx 7 
Re-CT 25 
Oropharynx 20 
Nasopharynx 5 
Re-plan 
Oropharynx 
Nasopharynx 
16 
13 
3 
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Table 3 Patient characteristic comparison planning intervention vs no 
planning intervention 
 
Characteristic Intervention SD No intervention SD 
SSD correction n=32  n=89  
Mean T classification 2 1.0 2 1.1 
Mean N classification 2 0.5 2 0.5 
Mean tumour 
differentiation 
Poorly or 
undifferentiated - 
Poorly or 
undifferentiated - 
Mean smoking 
history 
Former smoker - Former smoker - 
Mean nodal size 
(range) 
 
37.8mm*  
(14-70) 
14.2mm* 34.2mm* 
(13-90) 
15.3mm* 
Re-CT n=25  n=96  
Mean T classification 2 1.0 2 1.0 
Mean N classification 2 0.6 2 0.4 
Mean tumour 
differentiation 
Poorly or 
undifferentiated - 
Poorly or 
undifferentiated - 
Mean smoking 
history 
Former smoker - Former smoker   - 
Mean nodal size 
(range) 
 
44.2mm* 
(24-90) 
21.3mm* 32.7mm* 
(13-65) 
11.9mm* 
Re-plan n=16  n=105  
Mean T classification 2 1.2 2 1.0 
Mean N classification 2 0.6 2 0.4 
Mean tumour 
differentiation 
Poorly or 
undifferentiated - 
Poorly or 
undifferentiated - 
Mean smoking 
history Former smoker - Former smoker - 
Mean nodal size 
(range) 
44.8mm*  
(24-90) 21.5mm* 
33.2mm* 
(13-65) 12.8mm* 
* Removal of outlying measurement 
 
SSD corrections 
Thirty-two (26.4%) patients required an SSD correction to one or more 
treatment fields.  12.5% of patients required 2 to 3 corrections throughout 
treatment.  SSD corrections were performed at a median time point of 26 
fractions (range 5-34 fractions).  This corresponded with the commencement 
of the second phase of 3DCRT where field sizes were reduced to cover the 
high-risk tumour volume.  The mean dominant nodal size for patients who 
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had an SSD correction was 41 mm (+/- 14.2 mm).  Details for SSD 
corrections are given in Table 4. 
 
Table 4 SSD correction details 
 
Detail Number 
Median fraction SSD correction 
accounted for (range) 
26 (5-34) 
Median change in reference 
separation  
(range) 
1.5cm (0.2cm-2.6cm) 
Mean change in reference separation 1.6cm 
Median change in minimum spinal 
cord separation (range) 
1.6cm (0.2cm-3.4cm) 
Mean change in minimum spinal cord 
separation 
1.6cm 
Correction performed on basis of 
weekly separation measurements 
21 (65.6%) 
Correction performed on basis of re-
CT information 
11 (34.4%) 
 
 
Re-CT 
Twenty-five (20.7%) patients required a re-CT during their treatment. Table 5 
summarises the characteristics of patients who underwent a re-CT.  No 
treatment plan adaptation was required for 5 of these patients due to the 
negligible difference in dose distribution.  This was determined by the 
radiation oncologist and was based on dose volume histograms (DVHs) of 
target and critical structures.  Four of these patients had a SSD correction 
performed based on the information from the re-CT and 16 patients had a re-
plan generated.  Re-CTs were performed at a median time point of 22 (range 
0-29) fractions with one patient requiring a re-CT to be performed before the 
commencement of treatment.  The mean dominant nodal size for patients 
who underwent a re-CT was 44.2 mm (+/- 21.3 mm).  The most frequently 
occurring justification for a re-CT was a combination of weight loss and 
dominant nodal regression during treatment.  Two patients underwent a re-
CT for other reasons: one was rescanned due to set-up error and one was 
rescanned to re-plan the lower neck area as directed by the treating radiation 
oncologist. 
! 70!
Table 5 Re-CT details 
 
Detail Number 
No action from re-CT 5 (20%) 
SSD correction based on re-CT 4 (16%) 
Re-plan generated from re-CT 16 (64%) 
IMRT patients 4 (16%) 
Justification for re-CT  
Weight loss 9 
Primary tumour regression 0 
Nodal regression 3 
Combination 11 
Other 2 
Mean initial weight (kg) 82.8 
Mean weight at re-CT (kg) 76.9 
Mean weight loss (%) 7.1 
Mean initial primary GTV (cc) 30.9 
Mean primary GTV at re-CT (cc) 19.9 
Mean primary GTV reduction (%) 35.6 
Mean initial nodal GTV (cc) 59.8* 
Mean nodal GTV at re-CT (cc) 36.8* 
Mean nodal GTV reduction (%) 38.5 
* Removal of outlying measurement 
 
Re-plan 
Sixteen (13.2%) patients had a re-plan generated during their treatment, 
including 3 IMRT patients.  Of these 16 patients, 3 (18.8%) did not have their 
re-plan clinically actioned based on the fact that the DVHs of target and 
critical structures were clinically acceptable.  An SSD correction alone was 
performed on 7 (43.8%) patients and was based on the information from the 
re-CT only instead of employing the re-plan. Treatment adaptation occurred 
in 6 (37.5%) patients.  The majority of clinically actioned re-plans were 
calculated for implementation from fraction 26, the commencement of the 
second phase of treatment.  One re-plan was generated and implemented 
before the beginning of the patient’s treatment and one was implemented 
from fraction 2.  The mean number of working days between when the re-CT 
was performed and the implementation of the re-plan was 3 (range 1-5) days.  
The mean dominant nodal size in patients with a re-plan, irrespective of 
whether it was actioned or not, was 44.8 mm (+/- 21.5 mm). 
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Risk profiles 
Based on a preliminary evaluation of the adaptive planning intervention 
required in patients with VNHNC, there was a trend toward 3 risk profile 
groupings: 1) Low risk category with minimal need (< 10%) for adaptive 
treatment management.  This would include patients with a dominant pre-
treatment nodal size of 35 mm, 2) Intermediate risk category with a 
possible need (< 20%) for adaptive treatment management.  This would 
include patients with a dominant pre-treatment nodal size of 36 mm – 45 mm 
and 3) High-risk category with an increased likelihood (> 50%) for adaptive 
treatment management.  This would include patients with a dominant pre-
treatment nodal size of 	 46 mm.  The thresholds for these groupings were 
based on a combination of clinical experience and pre-treatment dominant 
nodal size for patients who had a re-CT or re-plan compared with those that 
did not.  Logistic regression models have demonstrated that these groups 
have a 62.5% positive predictive value and an 83% negative predictive value 
when based on pre-treatment nodal size and age.  CART analysis 
demonstrated a relationship between adaptive intervention and pre-
treatment nodal size (p-value <0.001), age (p-value 0.07) and initial weight 
(p-value 0.05).  It is important to note that a difference or exclusion of a lack 
of difference between the 3 groups could not be detected in the data analysis 
because of the limited sample size.  Results suggest that performing a re-CT 
at approximately fraction 20 may be beneficial for those in the intermediate 
and high-risk categories. 
 
Discussion 
Compared with traditional head and neck cancers, VMHNC’s tend to present 
with nodal disease, generally have a greater likelihood of response to RT 
and have a more favourable prognosis [5]. This can result in the need to re-
plan during treatment to maintain adequate coverage of the tumour and limit 
the dose to critical structures.  Clinician judgment currently plays a key role in 
deciding which patients require adaptive RT.  The need for a systematic 
approach to this issue and the determination of specific predictive factors has 
been previously highlighted [7, 9, 10].  Due to the variability in response and 
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the dynamic nature of the changes that occur throughout treatment to head 
and neck cancer patients, establishing these predictive factors presents a 
challenge.  As VMHNC patients in particular are living longer with the 
debilitating functional long-term side effects of treatment, it was felt that focus 
was required on which of these patients would benefit most from adaptive 
intervention to further minimize dose to surrounding tissues affecting quality 
of life.  We found that patients with VMHNC and nodal size ≥ 46 mm 
appeared to be a high-risk group that were more likely to be re-planned 
during a course of definitive RT.  Those patients who underwent adaptive 
planning intervention had a greater mean dominant node size than those 
who did not (Table 3).  Barker and colleagues [9] support this observation 
reporting that patients with larger tumours volumes required re-planning 
during their treatment.   
 
Adaptive radiotherapy is an approach to correct for morphological changes in 
patient anatomy including normal tissues and tumour volume variations as a 
result of treatment [6].  It can include both image-based modifications and 
treatment plan adjustments [2].  Image guidance throughout treatment is an 
essential component of adaptive RT.  The planning CT performed before the 
commencement of a patient’s treatment only provides a snapshot of their 
anatomy at this point in time and does not accurately represent the 
anatomical relationship between clinically important structures that may alter 
throughout the course of treatment [11].  The uncertainty surrounding the 
position, size and shape of normal and critical tissues during treatment has a 
potentially greater impact with the adoption of IMRT as the treatment of 
choice for these patients [11].  IMRT enables the generation of steep dose 
gradients that allow target volumes to be treated to high doses whist 
minimizing the dose delivered to surrounding normal and critical tissues [6].  
Consequently, minute changes in anatomy can result in dosimetric 
inaccuracies that produce significant impact on surrounding radiosensitive 
tissues [12].  This is demonstrated in our study where 4 of the 8 patients 
treated with IMRT underwent adaptive planning intervention and 3 patients 
had a re-plan generated.  Incorporation of standardized image guidance 
protocols into the adaptive RT strategy developed will enable a systematic 
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approach to monitoring these treatment-induced anatomical changes and 
prompting adaptive intervention.  CBCT may be used to monitor the patient 
daily on the treatment unit however, if a dosimetric adjustment is indicated, a 
re-CT is still required for accurate dosimetric calculation.  
 
The findings of this study are consistent with those of other investigations 
with some exceptions.   In a retrospective evaluation of IMRT patients, 
Jensen and colleagues [13] found that 15 of the 72 (20.8%) patients 
reviewed underwent plan adaptation at least once during their treatment 
compared with 38% for the present study.  The larger numbers of adaptive 
intervention in the present study may be a reflection that the majority of 
patients were treated with 3DCRT techniques.  The SSD correction 
intervention method described and employed for patients treated with 
3DCRT in this study is unable to be used with IMRT and was therefore not 
utilized in the Jensen study.  Excluding patients who underwent an SSD 
correction, the percentage of patients who had a re-CT in our study is 
comparable to the study by Jensen and his colleagues [13].  It is important to 
note that as IMRT is now the treatment of choice for VMHNC patients in our 
department, the SSD correction method is no longer routinely used.  The 
resultant impact is that there may be a higher percentage of patients 
requiring a re-CT and/or re-plan in the future.  The present study only 
evaluated patients with VMHNC.  The known increased radioresponsiveness 
of these tumours and their classic presentation of large nodes may have 
contributed to the higher percentage of patients requiring intervention in our 
study.  The variation between the studies may also be a result of the lack of 
a systematic approach to the use of adaptive interventions during the time of 
the present study.  
 
The majority of patients involved in this study were treated with 3DCRT as 
opposed to IMRT, however the technique utilized is not critical to the purpose 
of obtaining information on VMHNC treatment response and predictive 
factors indicating which patients will benefit most from adaptive RT.  
Consequently, these data provide a baseline and establish factors predicting 
the need for adaptive intervention that can be refined and further developed.  
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The inherent risk in retrospective studies, particularly the lack of control over 
the consistency of the data, means that cautious interpretation of the results 
should be undertaken.  Further analysis is required to develop the predictive 
model.  This was a direct result of no existing departmental guidelines on 
how to identify when patients require plan adaption.  However, a baseline for 
the development of appropriate risk profiles for this subgroup of patients has 
been established so that adaptive planning interventions can be determined 
and acted upon as required.  
 
Conclusion 
The use of adaptive radiotherapy techniques are important for VMHNC 
patients to ensure the delivery of the prescribed dose to target volumes 
whilst minimizing the dose to surrounding critical and normal tissues.  The 
generation of predictive factors and associated treatment management 
guidelines is of particular importance in determining the optimal process for 
the implementation of adaptive treatment planning.  This will provide 
maximum benefit, in terms of efficacy and efficiency, for both patients and 
busy radiotherapy departments.  A future prospective study is currently being 
designed to validate the findings of the present study. 
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Supplementary information 
Minimum spinal cord separation: 
The minimum spinal cord separation was defined as the smallest distance 
between the lateral skin surfaces of a patient through the level of the spinal 
cord.  This was determined on axial CT images in the treatment planning 
system.  Measurements to locate this point, relative to the isocentre, were 
recorded so that this point could be marked on the patient's shell for 
monitoring using callipers throughout treatment.  
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Chapter 5 
The purpose of this chapter was to assess dosimetric impact on target 
volumes and OAR of anatomical variation, directly relating to the first 
objective of this research.  The primary aim of this investigation was to 
evaluate the effect of treatment-induced anatomical changes, such as weight 
loss and tumour or nodal shrinkage, on the planned dose distribution to 
assist in the development of appropriate adaptive radiotherapy strategies. 
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ABSTRACT 
Introduction 
Patients with virally mediated head and neck cancer (VMHNC) often present 
with advanced nodal disease that is highly radioresponsive as demonstrated 
by tumour and nodal regression during treatment.  The resultant changes 
may impact on the planned dose distribution and so adversely affect the 
therapeutic ratio.  The aim of this study was to evaluate the dosimetric effect 
of treatment-induced anatomical changes in VMHNC patients who had 
undergone a re-plan. 
 
Methods 
Thirteen patients with virally mediated oropharyngeal or nasopharyngeal 
cancer who presented for definitive radiotherapy between 2005 and 2010 
and who had a re-plan generated were investigated.  The dosimetric effect of 
anatomical changes, was quantified by comparing dose volume histograms 
(DVH) of primary and nodal gross target volumes and organs at risk (OAR), 
including spinal cord and parotid glands, from the original plan and a 
comparison plan. 
 
Results 
Eleven 3DCRT and 2 IMRT plans were evaluated.  Dose to the spinal cord 
and brainstem increased by 4.1% and 2.6%, respectively.  Mean dose to the 
parotid glands also increased by 3.5%.  In contrast, the dose received by 
98% of the primary and nodal gross tumour volumes decreased by 0.15% 
and 0.3%, respectively when comparing the initial treatment plan to the 
comparison plan.  
  
Conclusion 
In this study, treatment-induced anatomical changes had the greatest impact 
on OAR dose with negligible effect on the dose to nodal gross tumour 
volumes.  
In the era of intensity modulated radiotherapy (IMRT), accounting for 
treatment-induced anatomical changes is important as focus is placed on 
minimising the acute and long-term side effects of treatment.   
! 82!
Introduction 
The emergence of virally mediated head and neck cancers (VMHNC) has 
presented the oncology community, and in particular radiation oncology, with 
some unique challenges.  These patients generally present younger, in 
better health compared with historical head and neck cancer patients, have 
radioresponsive disease and good prognosis, meaning that the development 
of strategies to minimise their long-term side effects is vital.1  
 
Head and neck cancer patients often experience numerous anatomical 
changes during treatment.2  These can be externally visible, including tumour 
and nodal regression and weight loss, and internal, including parotid gland 
volume changes.3,4  These changes may result in differences in dose 
distribution, causing potential underdosing of target volumes and/or 
overdosing of surrounding normal and critical tissue.5  This is of particular 
importance when highly conformal techniques, such as intensity modulated 
radiotherapy (IMRT) techniques are used because of the steep dose 
gradients that can be created between target volumes and surrounding 
normal and critical tissues.6  Adaptive radiotherapy is one dosimetric 
approach that can be employed to account for ongoing treatment-induced 
changes in anatomy and so minimise the impact on highly conformal IMRT 
dose distributions.7 
 
This study was a retrospective review of patients with VMHNC, who attended 
the Princess Alexandra Hospital (PAH) for definitive radiotherapy between 
2005 and 2010.  Patients who underwent a re-plan, due to anatomical 
changes identified by radiation therapists during their radiotherapy treatment 
course, were investigated.  Both virally mediated nasopharyngeal cancer 
(NPC) and oropharyngeal cancer (OSCC) were studied as collectively, these 
VMHNC's represent a subset of cancers that are clinically distinct.8  They 
have a greater likelihood of response to therapy, are not necessarily related 
to smoking, have a more favourable prognosis and a different pathway of 
malignant transformation.8  The primary aim of this investigation was to 
evaluate the effect of treatment-induced anatomical changes, such as weight 
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loss and tumour or nodal shrinkage, on the planned dose distribution to 
assist in the development of appropriate adaptive radiotherapy strategies. 
 
Methods and Materials 
Patients 
Patients with VMHNC who received definitive radiotherapy treatment with or 
without systemic therapy, between 2005 and 2010 were identified from a 
prospective head and neck database at PAH.  Eligibility criteria included: 
histologically confirmed NPC or OSCC, with either positive serology for 
Epstein Barr Virus (EBV) or Human Papillomavirus (HPV) (p16 
immunostaining >70%), respectively, and node positive disease with any T 
stage disease and treatment plan accessible on the treatment planning 
system.  Patients who had a re-plan generated during their treatment were 
selected in order to examine the volumetric and dosimetric changes between 
the planning scan and the repeat planning CT scan (re-CT).  At the time of 
the study, there was no protocol to identify patients requiring re-planning and 
decisions were made based on the treating radiation therapists’ judgement 
on a daily basis.  These decisions were informed by the evaluation of the 
mask fit and assessment of weekly separation measurements.  If a change in 
separation reading of greater than 1cm occurred, the plan was returned to 
planning for review and potential re-CT.  Patient demographics and tumour 
characteristics, including pre-treatment size of the dominant node, were 
recorded.  Nodal size data was collected from each patient’s diagnosis and 
staging information.  Patient weight was measured by a radiation oncology 
nurse or dietician at the time of planning and at re-CT. The project was 
approved by the Human Research Ethics Committees from the PAH and 
Queensland University of Technology. 
 
Re-CT and volumetric change evaluation 
Each patient’s re-CT was performed in the same position as the planning CT.  
The re-CT was manually fused with the planning CT using the registration 
match point/region prescribed by the radiation oncologist and this registration 
was checked by both a senior radiation therapist and the radiation oncologist.  
The primary and nodal gross target volumes and specific organs at risk 
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(OAR) were re-contoured by a radiation oncologist on the re-CT to determine 
if any volumetric changes had occurred.  The same radiation oncologist did 
not contour these volumes on both the planning CT and re-CT in all cases.  
The volumes were recorded for the primary and nodal gross target volumes 
and left and right parotid glands.   
 
Dosimetric effect evaluation 
The effect of any treatment-induced anatomical changes on the dose 
distribution was quantified by comparing the primary plan with a comparison 
plan.  All plans were calculated on the Eclipse treatment planning system 
(version 8.6, Varian Medical Systems, Palo Alto, CA, USA).  The primary 
plan was calculated using the original CT data.  The comparison plan used 
the same treatment fields from the primary plan but calculated on the re-CT 
data.  The monitor units (MU) for all treatment fields remained the same for 
both plans to ensure that the dosimetric effect of anatomical changes could 
be accurately recorded.  For three-dimensional conformal (3DCRT) plans, 
the comparison plan was created by one radiation therapist who replicated 
the primary plan, at the same isocentre position, using the re-CT data.  The 
plan was then calculated and doses adjusted to represent the treatment 
portions delivered before and after the observation of anatomical changes.  
For IMRT plans the fluence map from the primary plan was used to calculate 
the comparison plan.  The dosimetric effect was quantified by comparing 
dose volume histograms (DVH) of primary and nodal gross target volumes 
(GTV-p and GTV-n) and OAR from both plans.  OAR investigated were 
spinal cord, brainstem and left and right parotid glands.  
 
Statistics 
Data were analysed using the Stata (version 12.1, StataCorp LP, Texas, 
USA) program. Doses to target volumes and OAR were recorded from both 
the initial and comparison plans.  The re-CT data was also examined to 
assess volumetric changes in tumour, nodal and parotid volumes and weight 
loss.  Statistical analysis included basic descriptive statistics to determine the 
impact of treatment-induced anatomical changes on the dose distribution.  
Mann-Whitney-Wilcoxon tests were used to analyse the comparison of 
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changes in volume and dose of target volumes and OAR for the initial plan 
and the comparison plan.  A p-value of 0.05 was considered statistically 
significant.  
 
Results 
Patient characteristics 
Sixteen patients had a re-plan calculated and were selected for the study.  
Three patients were excluded from this investigation.  Of these, one was 
unable to be retrieved from archive, one primary treatment plan was not 
utilised as the patient returned at a later date to receive treatment and one 
was only planned to receive a dose of 50 Gy.  The demographics of these 
patients are shown in Table 1.  Eleven patients were male and 2 were female, 
10 patients had HPV-positive OSCC and 3 had EBV-positive NPC.  Five 
(50%) of oropharynx patients were staged as having T2-3N2 disease and 2 
(66.7%) nasopharynx patients, T4N2 disease.   Eleven patients in this study 
were treated with 3DCRT and 2 patients were treated with IMRT.  All patients 
were prescribed and treated to a total dose of 70 Gy in 35 fractions.  The 
details of the prescription and OAR tolerances used are outlined in Table 2.  
At least one parotid gland was spared where possible, ideally to a mean of < 
26 Gy, but up to a mean of 33 Gy, as the specified tolerance dose.9  Re-
plans were generated at a mean time point of fraction 22 (range 17-29).    
Eight (61.5%) patients underwent a re-CT and re-plan due to a combination 
of 2 factors: weight loss and tumour and/or nodal regression.  The reason for 
re-CT and re-plan for the remaining 5 patients were weight loss or tumour 
regression alone and a pre-scheduled re-plan of the lower neck area.  Only 3 
of the 13 (23.1%) patients actually had the plan from the re-CT clinically 
implemented.  This was due to the fact that the DVHs of target and OAR 
were considered clinically unacceptable by the treating radiation oncologist. 
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Table 1 Patient characteristics 
  Characteristics 
Sex  
Male 11 
Female 2 
Age mean (range) 50 (36-64) 
Primary tumour site  
Tonsil 6 
Base of tongue 4 
Nasopharynx 3 
T classification  
1 1 
2 5 
3 3 
4 4 
N classification  
1 1 
2 8 
3 4 
Smoking history  
Never 4 
Former 3 
Active 6 
Nodal size mean (range) 48.8mm (24mm-90mm) 
Treatment technique  
3DCRT 11 
IMRT 2 
Mean timing of re-CT #22 (#17-#29) 
Re-plan implemented 3 
 
3DCRT - three-dimensional conformal radiation therapy 
IMRT - intensity modulated radiation therapy 
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Table 2 Prescription and OAR dose tolerances 
 
Structure Dose 
Prescription 70Gy in 35# 
Spinal cord ≤ 45Gy 
Brainstem ≤ 54Gy 
Parotid glands Mean dose ≤ 33Gy 
 
Weight loss and volume reduction 
The weight loss and volume changes for GTVs and the parotid glands are 
demonstrated in Figure 1 and Table 3.  All patients experienced weight loss 
during treatment.  The overall mean percentage weight loss was 6.5%.  
Reduction in volume was observed for both target volumes and all OAR 
studied however, only the GTV-p and GTV-n approached statistical 
significance (p=0.06 and p=0.09).  The greatest mean volume reduction 
seen was for the GTV-n with a 50.8% reduction being recorded.  One patient 
was excluded from the GTV-p results due to incomplete volumes.  The 
greatest percentage mean volume change for OAR was recorded for the 
parotid glands with a volume reduction of 21.8% and 26.4% for the left and 
right glands respectively. 
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Figure 1 (a–d) Volume changes of (a) primary gross target volume 
(GTV-p), (b) nodal gross target volume (GTV-n), (c) left parotid 
gland and (d) right parotid gland between the planning CT and 
Re-CT. The box represents standard deviation (SD), and the 
horizontal line in the box represents the mean of the volumes. 
The bar represents the range of the volumes.  The dots 
represent outlying measurements. 
 
  
!!! !
(a) (b) 
 
    
(c)                                                           (d) 
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Table 3 Mean weight and volume reduction details 
Structure Planning CT 
(range) 
Re-CT 
(range) 
Difference p-value 
Mean weight 
(kg) 
81.7  
(51.8 - 127.5) 
76.4 
(42.9 - 116.6) 
5.3  
(6.5%) 
0.40 
Mean GTV-p* 
volume (cc) 
32.3 
(14.9 - 52.3) 
22.6 
(0.4 - 49.1) 
9.7 
(30%) 
0.06 
Mean GTV-n 
volume (cc) 
56.1 
(6.4 - 240.2) 
27.6 
(3.8 - 116.6) 
28.5 
(50.8%) 
0.09 
Mean Lt 
Parotid volume 
(cc) 
24.8 
(9.1 - 53.4) 
19.4 
(7.9 - 38.6) 
5.4 
(21.8%) 
0.27 
Mean Rt 
Parotid volume 
(cc) 
25.0 
(9.5 - 48.8) 
18.4 
(7.8 - 31.6) 
6.6 
(26.4%) 
0.15 
* One patient excluded due to incomplete voluming 
GTV-p - primary gross target volume 
GTV-n - nodal gross target volume 
 
Dosimetric effect 
The details of the dose comparison between the primary plan and the 
comparison plan are demonstrated in Table 4.  The mean dose 
encompassing 98% of the GTV-p and GTV-n volumes (D98) was slightly 
decreased when comparing the primary plan with the comparison plan.  In 
contrast, the mean doses to all OAR investigated increased with the greatest 
increase being for the maximum spinal cord dose (4.1%).  Eleven (84.6%) 
patients had an increase in dose to 2 or more OAR when comparing the 
primary plan with the comparison plan.  While none of the differences were 
statistically significant (p>0.05), greater dose variations and larger standard 
deviations were observed for the OAR in comparison to the target volumes.  
The GTV-p had a range of 61.7 Gy to 70.1 Gy and the GTV-n had a range of 
58.9 Gy to 71.1Gy.  The left parotid had a range of 35.1 Gy and 69.3 Gy and 
and the right parotid had a range of 31.3 Gy and 68.6 Gy.  This is consistent 
! 90!
with the primary planning objective of covering the target volumes with the 
prescribed dose.   
 
The observed range of treatment-induced anatomical changes experienced 
resulted in a larger dosimetric effect in some patients.  In one patient, 
anatomical changes resulted in only a minimal change in target volume D98 
dose (-0.2% and 2.2% in GTV-p and GTV-n respectively) but a much greater 
impact on OAR doses; 4.2% increase in maximum spinal cord dose and 
13.4% and 8% increase in left and right parotid gland mean doses 
respectively. 
 
Table 4 Mean doses to tumour and OAR volumes 
Structure Primary plan  
± SD (Gy)  
Comparison 
plan ± SD (Gy) 
Difference 
(Gy) 
p-value 
Mean GTV-p 
D98* 
66.9 ± 2.6 
 
66.8 ± 2.7 
 
-0.1  
(-0.15%) 
0.95 
Mean GTV-n 
D98 
67.6 ± 2.8 
 
67.4 ± 3.9 
 
-0.2 
(-0.3%) 
0.83 
Mean Plan 
max 
77.2 ± 1.8 
 
76.9 ± 1.9 
 
-0.3 
(-0.39%) 
1.00 
Mean Spinal 
cord max 
43.6 ± 3.8 
 
45.4 ± 4.8 
 
1.8 
(4.1%) 
0.47 
Mean 
Brainstem max 
42.1 ± 14.0 
 
43.2 ± 11.8 
 
1.1 
(2.6%) 
0.88 
Lt Parotid 
mean 
51.9 ± 12.6 
 
53.6 ± 12.0 
 
1.7 
(3.3%) 
0.50 
Rt Parotid 
mean 
45.0 ± 13.1 
 
46.6 ± 14.3 
 
1.6 
(3.6%) 
0.80 
* One patient excluded due to incomplete voluming 
OAR - organ at risk 
SD - standard deviation 
GTV-p - primary gross target volume 
GTV-n - nodal gross target volume 
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Discussion 
This study showed that treatment-induced anatomical changes had the 
greatest impact on the OAR, increasing the doses received with negligible 
dose decrease to the primary and nodal GTVs.  These results, while not 
statistically significant, are of clinical importance as the observed dosimetric 
impact could result in the tolerance dose of an OAR being exceeded.  As an 
example, one patient studied was originally planned to receive a maximum 
spinal cord dose of 46.2 Gy but due to treatment-induced anatomical 
changes, received 54.1 Gy.  This overdosing of OAR can result in increased 
acute and long-term toxicity experienced by the patient and a reduction in 
their overall quality of life.  Consequently, it is imperative that the effect of 
these anatomical changes is considered and accounted for.  This is of 
particular importance with the parotid glands as, due to their steep dose-
response relationship, exceeding the tolerance dose could result in 
permanent loss of salivary function.10   
 
Previous studies have also demonstrated the decrease in volume and 
subsequent increase in dose received by the parotid glands.7,11-14  Beltran 
and colleagues15 have reported an increase of 2.5 % in spinal cord dose and 
an increase of 4.7 % and 6.7 % in mean parotid gland dose during head and 
neck IMRT.  In contrast to the present study, they also reported a significant 
decrease in dose (D98) to the primary target volumes (p value=0.01).15  This 
difference could be due in part to the fact that only GTV dose coverage was 
measured in the present study whereas the study by Beltran primarily 
reported the planning target volume (PTV) dose.  When specifically focusing 
on the GTV D98 dose, only a slight effect is observed: a 0.2% decrease in 
the present study and a 0.4% increase in the Beltran study.  In addition, only 
patients receiving IMRT were reported by Beltran and colleagues whereas 
the majority of patients in the present study were treated with 3DCRT.  It is 
well recognised that the steep dose gradients created with IMRT can make it 
more sensitive to treatment-induced anatomical changes, resulting in 
potential underdosing and/or overdosing of target and OAR volumes.5,12,15  
The dosimetric effect observed in patients who received 3DCRT, may be 
magnified under IMRT, particularly for OAR such as the parotid glands which 
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are known to shift medially into higher dose areas with weight loss and 
tumour regression.3  The added workload associated with the re-planning 
process can place substantial burden on busy radiotherapy departments and 
further highlights the importance of appropriate, evidence-based adaptive 
radiotherapy protocols for head and neck IMRT.16  The wide range of parotid 
gland doses observed in the study may be related to a number of factors: 
initial parotid size, differences in disease pathology, differential shrinkage of 
the surrounding nodes and the improvement in radiotherapy treatment 
techniques used over the study period. 
 
The adaptive radiotherapy protocols developed as part of this study will be 
tested in conjunction with daily image guidance using volumetric imaging 
allowing the exact timing of treatment-induced anatomical changes to be 
determined.  This will enable accurate evaluation of their dosimetric impact 
and will maximise the benefit of adaptive intervention.    Comprehensive 
assessment of the dosimetric impact of anatomical changes was not possible 
in the present study as daily volumetric imaging was not used.  As a result, 
the exact time point at which they occurred could not be determined.  The re-
CTs used for dosimetric evaluation were performed after treatment staff had 
observed the anatomical changes. 
 
The inherent risk in retrospective studies, particularly the lack of control over 
data consistency, in combination with the small sample size means that 
cautious interpretation of the results should be undertaken.  It is likely the 
small sample size meant the study was insufficiently powered to detect any 
significant differences.  Another limitation of the study was that the variability 
in contouring of target and OAR volumes between the planning CT and re-
CT was not accounted for and may have impacted the volumetric and 
dosimetric results.  Nonetheless, the results of this study support the 
dosimetric impact of treatment-induced changes and provide baseline data 
for the development of appropriately focused adaptive treatment strategies.  
The clinically important dosimetric effect on OAR demonstrated in this study 
warrants further investigation with a larger sample size. 
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Conclusion 
In this study, treatment-induced anatomical changes had the greatest impact 
on OAR dose.  The dosimetric impact observed is of clinical consequence 
and could potentially lead to exceeding an OAR tolerance dose.  The 
development of adaptive radiotherapy strategies targeted at reducing OAR 
dose, while maintaining target volume dose, will be of great importance to 
patient long-term quality of life and departmental efficiency.  In the era of 
IMRT, accounting for treatment-induced anatomical changes is paramount 
due to the steep dose gradients between target volumes and OAR.  This is of 
particular relevance to patients with VMHNC as their increased 
responsiveness to radiotherapy often leads to a favourable prognosis. 
Although this study investigated only VMHNC, the adaptive radiotherapy 
strategies developed using these findings and associated dosimetric impact 
will be evaluated in a larger prospective study including all head and neck 
cancer patients with stratification between VMHNC and non-VMHNC patients.  
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Chapter 6 
The purpose of this chapter was to identify predictive factors that pre-dispose 
HNC patients to being more likely to require ART to form a predictive model 
and risk profiles, the second objective of this research.  This risk profile 
approach could facilitate the effective implementation of ART into 
radiotherapy departments through forward planning and appropriate 
resource allocation.  This paper describes the prospective phase of this 
research that was conducted in multiple institutions. 
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ABSTRACT 
 
Background and Purpose 
Adaptive radiotherapy (ART) can account for the dosimetric impact of 
anatomical change in head and neck cancer patients; however it can be 
resource intensive.  Consequently, it is imperative that patients likely to 
require ART are identified.  The purpose of this study was to find predictive 
factors that identify oropharyngeal squamous cell carcinoma (OPC) and 
nasopharyngeal carcinoma (NPC) patients more likely to need ART. 
 
Materials and Methods 
One hundred and ten patients with OPC or NPC were analysed.  Patient 
demographics and tumour characteristics were compared between patients 
who were re-planned and those that were not.  Factors found to be 
significant were included in logistic regression models.  Risk profiles were 
developed from these models.  A dosimetric analysis was performed. 
 
Results 
Nodal disease stage, pre-treatment largest involved node size, diagnosis and 
initial weight (categorised in 2 groups) were identified as significant for 
inclusion in the model.  Two models were found to be significant (p=0.001), 
correctly classifying 98.2% and 96.1% of patients respectively.  Three ART 
risk profiles were developed. 
 
Conclusion 
Predictive factors identifying OPC or NPC patients more likely to require ART 
were reported.  A risk profile approach could facilitate the effective 
implementation of ART into radiotherapy departments through forward 
planning and appropriate resource allocation. 
 
  
! 102!
Introduction 
Highly conformal, modulated techniques, such as intensity modulated 
radiation therapy (IMRT), helical IMRT (Tomotherapy) and volumetric 
modulated arc therapy (VMAT) are considered the standard radiotherapy 
techniques for the treatment of head and neck squamous cell carcinomas 
(HNSCC).[1-3]  These techniques enable delivery of high radiation doses to 
tumour volumes whilst minimising dose to surrounding structures with 
resultant reduction in toxicities experienced by patients.[4]  However, 
geometric and anatomical changes that can occur over a treatment course 
may limit the benefits associated with these highly conformal techniques and 
should be considered when developing appropriate treatment approaches.[2]  
Anatomical changes can be attributed to a number of factors including 
shrinkage of tumour and nodal volumes, changes in tumour position and 
weight loss.[5, 6]  Various adaptive radiotherapy (ART) techniques have 
been evaluated to assess their effectiveness in addressing this issue 
however the ART process can be resource intensive on departments with re-
planning procedures requiring both additional use of planning equipment and 
staff time.[6, 7]  Consequently, it is imperative that patients who are likely to 
require ART are properly identified.  This will facilitate the effective 
implementation of ART into radiotherapy departments by forward planning, 
resulting in gains in efficiency and appropriate allocation of departmental 
resources.  ART in this context refers to the generation of a new radiotherapy 
plan based on imaging performed during a patient’s treatment course that 
accounts for anatomical changes.   
 
The majority of studies have primarily investigated factors that determine the 
requirement for ART whilst a patient is undergoing treatment.  There is little 
published data on identifying factors that could predict the need for ART prior 
to the commencement of treatment.  As patient selection for ART can be 
subjective, the focus of this study was to identify characteristics that pre-
dispose patients to being more likely to require ART.  Consequently, the 
primary aim of this project was to find predictive factors that identify 
oropharyngeal squamous cell carcinoma (OPC) and nasopharyngeal 
carcinoma (NPC) patients more likely to need ART.  These predictive factors 
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would be used to refine a risk profile approach previously developed.  OPC 
and NPC were chosen as they both commonly present with nodal 
involvement, have a high rate of viral association (Human Papillomavirus 
(HPV) with OPC and Epstein Barr Virus (EBV) with NPC) and respond well 
to radiotherapy treatment. 
 
Materials and Methods 
Patients 
Between October 2013 and December 2014, 110 patients were recruited 
from three tertiary radiotherapy departments in Brisbane, Australia to join a 
prospective cohort study.  This study was approved by the Princess 
Alexandra Hospital and Royal Brisbane and Women’s Hospital Human 
Research Ethics Committee.  Informed consent was obtained.  Eligibility 
criteria included: histologically confirmed NPC or OPC, or metastatic cervical 
nodal disease of unknown primary suspected of arising from either the 
oropharynx or nasopharynx; absence of distant metastatic disease; 
treatment with radical radiotherapy with any IMRT technique including 
rotational arc or helical radiation therapy techniques; a radiation prescription 
dose of ≥50Gy and with or without concurrent chemotherapy.   Patients were 
excluded: if it was unknown whether their disease was virally associated or 
not; if they had undergone definitive resection of the primary tumour, and/or 
a neck dissection; if they were treated with a three-dimensional conformal 
radiotherapy technique and if there was an inability to spare at least one 
parotid gland (i.e. unable to achieve a mean parotid dose of ≤ 26Gy[8] - 
33Gy[9]).  Patient demographics, tumour characteristics (including pre-
treatment size of the dominant node) and treatment details were recorded.  
Nodal size data was collected from each patient’s diagnosis and staging 
information. 
 
Treatment planning 
All patients were positioned supine, immobilised in a thermoplastic mask 
covering the head and shoulder region.  Patients underwent computed 
tomography (CT) simulation procedures according to standard departmental 
protocol and all CT scans were obtained using a helical CT scanner with 3 
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mm slice spacing.  Intravenous (IV) contrast was not used for CT scanning 
as all patients had a positron emission tomography (PET)/CT fused with the 
planning CT for volume definition.  Magnetic resonance imaging (MRI) scans 
were fused as appropriate with the planning CT scan to aid in target 
delineation.  Target volumes were contoured according to the department’s 
standard protocol. 
 
ART management 
Re-CT 
Consented patients were allocated to one of three ART risk profiles primarily 
based on the pre-treatment size of their largest involved node, as previously 
described.[10]  These risk profiles indicated which patients would have a 
second planning computed tomography (CT) scan (re-CT) booked prior to 
treatment commencement at fraction 15.  Patients had a daily, pre-treatment 
cone beam CT (CBCT) or megavoltage CT (MVCT) scan taken.  This scan 
was used during the treatment session to correctly align the isocentre.  
Scans were reviewed on a weekly basis by one of four Radiation Therapists 
to assess the need for the patient to undergo a re-CT for ART purposes.  For 
all patients, a re-CT was performed if the difference between the planning 
scan and the CBCT was greater than 1 cm at any point of the patient’s 
external contour within the treatment area.  The only circumstance where a 
re-CT was not required was if the patient had seven fractions or less 
remaining in their treatment.   
 
If a difference greater than 1 cm was noted for a patient receiving 
Tomotherapy, the original plan was re-calculated on the MVCT to make an 
initial assessment of the dosimetric impact of the anatomical change.   On 
plan review, if the Radiation Oncologist considered the dosimetric impact to 
be clinically significant, a re-CT was performed.  A flow chart outlining the 
study procedure is demonstrated in Supplementary Figure 1. 
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Supplementary Figure 1 Flow chart outlining study procedure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment for need of re-plan 
For all patients that had a re-CT, the original CT and the re-CT were fused 
using rigid registration according to the region of interest specified by the 
Radiation Oncologist to assess the requirement for a new treatment plan (re-
plan).  The original plan was translated to the re-CT dataset and calculated 
using the original monitor units (MU).  This method is similar to the hybrid 
technique described by Hansen et al.[6]  The treating Radiation Oncologist 
Consent of eligible patients 
Allocation to appropriate risk profile (Brown et al 2013) !
Low risk 
Dominant pre-treatment 
nodal size ≤ 35mm !
Intermediate risk 
Dominant pre-treatment nodal size 
36mm – 45mm !
High risk 
Dominant pre-treatment 
nodal size ≥ 46mm 
• All patients have daily volumetric imaging (CBCT or MVCT) 
o Used daily for treatment positioning 
• All images reviewed weekly to determine need for re-CT 
o Difference between planning and treatment external contour >1cm 
o Not applicable if <7 treatment fractions remaining 
Refinement of preliminary risk profiles !
No re-CT required ! Re-CT required Assessment of dosimetric impact 
• Original plan calculated on re-CT 
• Radiation Oncologist review to 
determine need for re-plan 
o DVH 
o Visual inspection of isodoses 
No re-plan 
required 
Re-plan required 
• Must be 
implemented 
in < 5 working 
days !
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assessed the image registration and any volumetric deformations or 
positional shifts of target or organ at risk (OAR) structures and reviewed the 
plan through both visual inspection and evaluation of the dose volume 
histogram (DVH).  Nodal gross tumour volumes (GTV-n), serial OAR and 
parotid glands were re-contoured.  The decision to generate a re-plan was at 
the discretion of the treating Radiation Oncologist.  Factors influencing a 
Radiation Oncologist’s decision to re-plan included critical OAR, such as the 
spinal cord or optic structures, receiving dose above the accepted tolerance 
level and inadequate target volume coverage. 
 
Doses received by the GTV-n, non-target tissue (NTT), spinal cord, 
brainstem and parotid glands were recorded from both the original plan and 
the delivered dose plan to assess dosimetric impact.  
 
Re-plan 
If a re-plan was necessary, target and OAR structures were re-contoured as 
required on the re-CT and a new plan generated.  The aim of the new plan 
was to achieve at least comparable target volume coverage and OAR doses 
to the original plan. 
 
Statistics 
Patients who required a re-plan were compared with those that did not to 
identify common characteristics among the re-plan group.  A three-stage 
approach was taken to the statistical analyses.  For the first step, univariate 
and multivariate analyses were used including Chi squared[11] and Mann-
Whitney[12] tests to compare various factors between the two groups.  
Comparison of dosimetric factors was conducted between the original 
treatment plan and the delivered dose using the Wilcoxon matched-pairs 
signed-ranks test.  These tests were used as the data was not normally 
distributed.  Tested factors included gender, age, diagnosis, disease stage, 
viral status, initial weight and initial size of the pre-treatment dominant node.  
A p-value of ≤ 0.05 was considered statistically significant.  For the second 
stage logistic regression was used to model the relationship between the 
categorical outcome and explanatory variables. The explanatory variables 
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used were determined in stage one.  Logistic regression was used as the 
outcome being investigated was binary (i.e. re-plan).  In the regression 
analyses, the binary response variable was the requirement for a re-plan and 
a p-value of p ≤ 0.05 was considered to be statistically significant.  Data was 
analysed using the Stata (version 12.1, StataCorp LP, Texas, USA) program.  
For the third stage, classification and regression trees (CART) were used to 
identify interacting relationships between explanatory variables and the 
categorical response variable. Only the identified explanatory variables were 
included in the CART analysis.  CART analysis was performed in RStudio 
version 0.98.110 [13] using the rpart.plot package.[14] 
 
Results 
Patients 
Patient characteristics and treatment details are summarised in Table 1.  The 
cohort comprised of 91.8% males with the primary diagnosis being OPC in 
84.5% and NPC in 11% of patients.  In this cohort, 84.5% of patients had 
HPV or EBV positive disease.  Of the 110 patients, 21 (19.1%) had a re-CT 
with 5 (4.5%) resulting in a re-plan.  Of the 5 patients that were re-planned, 3 
(60%) had a primary diagnosis of NPC.  Patients who underwent re-planning 
only had one new plan generated. 
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Table 1 Patient characteristics and treatment details 
Characteristic Value (range) 
Sex 
Male 
Female 
 
101 
9 
Median age (years) 59 (28-74) 
Diagnosis 
Oropharynx 
Nasopharynx 
Carcinoma of unknown primary 
 
93 
12 
5 
T classification 
0 
1 
2 
3 
4 
 
7 
17 
37 
23 
26 
N classification 
0 
1 
2 
3 
 
2 
12 
88 
8 
Viral status 
Positive 
Negative 
 
93 
17 
Median smoking history (pack years) 13 (0-100) 
Median initial node size (mm) 30 (6-80) 
Median initial weight (kg) 87.9 (42-150.9) 
Median percentage weight loss 
during treatment (%) 
9.9 (-0.9-28.5) 
Treatment technique 
IMRT 
VMAT 
Tomotherapy 
 
32 
67 
11 
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Patient characteristics comparison 
The comparison of patient characteristics for those that had a re-plan and 
those that did not is displayed in Table 2.  Patients who were re-planned had 
significantly more advanced nodal disease (p<0.0001), with the majority of 
patients having N2 or higher disease, and larger pre-treatment dominant 
nodal size (p=0.007).  A significant difference was found between diagnoses 
(p=0.001); with the majority of re-plan patients having NPC, and treatment 
technique (p=0.044) with all re-plan patients being treated with VMAT or 
Tomotherapy.  All re-planned patients had viral positive disease.  
Chemotherapy was not found to be a significant factor in the need for a re-
plan.  No other characteristics were found to be statistically significant.  
However, when initial patient weight was split into two categories, those with 
an initial weight less than 100kg and those greater than 100kg, a difference 
approaching significance was noted (p=0.07) with re-planned patients having 
a greater initial weight. 
 
 
 
 
Chemotherapy 
Cisplatin 
Cetuximab 
Other 
Ceased 
 
78 
20 
1 
2 
Median prescribed radiation dose 
(Gy) 
70 (67-70) 
Re-CT 
Oropharynx 
Nasopharynx 
21 
15 
6 
Re-plan 
Oropharynx 
Nasopharynx 
5 
2 
3 
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Table 2 Characteristics comparison between patients that had a re-plan 
and those that did not 
Characteristic No re-plan  
(range) 
n=105 
Re-plan  
(range) 
n=5 
p-
value 
Sex 
Male 
Female 
 
96 
9 
 
5 
0 
0.494 
Median age (years) 59 (29-74) 52 (28-71) 0.347 
Diagnosis 
Oropharynx 
Nasopharynx 
Carcinoma of unknown 
primary 
 
91 
9 
5 
 
2 
3 
0 
0.001* 
T classification 
0 
1 
2 
3 
4 
 
1 
16 
36 
22 
24 
 
0 
1 
1 
1 
2 
0.863 
N classification 
0 
1 
2 
3 
 
2 
11 
87 
5 
 
0 
1 
1 
3 
<0.001* 
Viral status 
Positive 
Negative 
 
88 
17 
 
5 
0 
0.328 
Median smoking history 
(pack years) 
11 (0-100) 35 (0-50) 
0.362 
Median initial node size 
(mm) 
30 (6-80) 70 (29-70) 0.007* 
Median initial weight (kg) 87.8 (42-150.9) 101.4 (57-130) 0.385 
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* indicates statistical significance (p<0.05) 
 
Predictive model 
Factors found to be significant or approaching significance in the multivariate 
analysis were included in the logistic regression model. After initial testing, 
technique was not statistically significant and was removed from the model.  
As having virally disassociated disease predicted failure perfectly, viral status 
was unable to be included in the model.  Two models were found to best 
predict the need to re-plan during treatment: 
 
Model 1  
Logit# (re-plan) = -23.168 + (2.416*N stage) + (5.958*diagnosis) + 
(0.150*initial node size) + (9.562*weight_2 categories) 
Model 2 
Logit# (re-plan) = -25.218 + (4.031*N stage) + (7.876*diagnosis) + 
(0.142*initial node size) + (10.70*weight_2 categories) 
 
# Logit = log of the odds [log(p/1-p)] 
 
The second model was weighted according to the proportion of patients that 
were re-planned in order to increase the sensitivity of the model and place 
greater importance on the requirement to predict patients who will require a 
re-plan.[15]  The first model was not weighted.  The result of post estimation 
testing of both models is displayed in Table 3. 
 
 
Median percentage weight 
loss during treatment (%) 
9.6 (-0.9-28.5) 11.6 (8.6-18.9) 
0.116 
Treatment technique 
IMRT 
VMAT 
Tomotherapy 
 
32 
64 
9 
 
0 
3 
2 
0.044* 
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Table 3 Post estimation results for logistic regression models 
 Model 1 Model 2 
p-value 0.001 0.001 
Pseudo R2 0.6153 0.7505 
Sensitivity 60% 100% 
Specificity 100% 92.31% 
Positive predictive value 100% 92.59% 
Negative predictive value 98.11% 100% 
Correctly classified 98.2% 96.1% 
Misclassified 0 8 
 
ART risk profiles and CART analysis 
The predictive models were used to determine threshold values for inclusion 
in ART risk profiles that could be implemented clinically.  High risk was 
classed as having a greater than 80% probability for requiring a re-plan and 
intermediate risk, greater than 60% probability for requiring a re-plan.  Low 
risk encompassed the remainder of patients.  The ART risk profiles are 
displayed in Table 4.   
Table 4 ART Risk Profiles 
Diagnosis 
ART Risk Profile 
Low Intermediate High 
Oropharynx Initial node size <45mm 
• Stage N2-3 disease 
• If initial weight <100kg 
o Initial node size >110mm 
• If initial weight >100kg 
o Initial node size 45-
55mm 
• Stage N3 disease 
• Initial weight >100kg 
• Initial node size 
>55mm 
Nasopharynx 
• If initial weight <100kg 
o Initial node size 
<60mm 
• If initial weight >100kg 
o Initial node size 
<15mm 
 
• Stage N2-3 disease 
• Initial weight <100kg 
• Initial node size 
>60mm 
 
• Stage N2-3 disease 
• Initial weight >100kg 
• Initial node size 
>15mm 
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These predictive factors were also used in the CART analysis, the results of 
which are displayed in Figure 1. 
 
 
Figure 1 CART predicting the need to re-plan.  To read the CART, start 
at the first node, which represents the whole cohort, and follow the decision 
tree as appropriate for the patient to the final node in that branch.  The first 
line in each node states the probability of re-plan for that branch, the second 
line provides the number and percentage of patients who are categorised in 
that branch.   
 
Re-CT patient dosimetric comparison 
A significant difference was found between the median original planned dose 
and delivered dose for the GTV-n D98 (near minimum dose), GTV-n D2 
(near maximum dose), NTT, and spinal cord maximum doses and parotid 
gland mean doses (p<0.05) (Table 5).  In all cases, the delivered dose was 
greater than the planned dose.  This increase in dose equated to ≤1% in all 
structures except the ipsilateral parotid gland (2.8%) and contralateral parotid 
gland (3.6%) with GTV-n coverage still within +/- 105% and OAR median 
doses less than the prescribed tolerance.  
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Comparison of dosimetric impact between patients who only had a re-CT 
and those selected for re-planning (prior to calculation of the re-plan), 
showed that re-planned patients had a significantly greater ipsilateral parotid 
gland dose (p=0.02) (Table 5).  Delivered doses were also greater for the 
spinal cord and brainstem maximum dose and mean contralateral parotid 
gland doses, with the spinal cord and brainstem approaching statistical 
significance (p=0.06 and p=0.07 respectively).  When a re-plan was 
calculated for selected patients, OAR doses were reduced to be equivalent 
to the originally planned dose. 
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Table 5 Dosimetric characteristics of all re-CT patients and delivered 
median dose comparison between patients who had a re-CT only and those 
who were selected for re-planning (before re-plan calculated) 
 
 
* indicates statistical significance 
GTV-n=nodal gross tumour volume, D98=dose received by 98% of structure, 
D2=dose received by 2% of structure, NTT=non target tissue 
 
Discussion 
Tumours in the head and neck region can undergo considerable anatomical 
changes during the course of radiotherapy, potentially leading to suboptimal 
dose distributions and overdosing of serial OAR.  This study found that NPC 
patients with more advanced nodal disease and an initial weight greater than 
100kg had the greatest likelihood of requiring a re-plan during treatment.  
ART has proved to be beneficial in maintaining tumour volume coverage and 
Structure 
All re-CT patients 
Re-CT only 
(range) (Gy) 
Selected for 
re-plan 
(range) (Gy) 
p-value 
Planned 
median dose 
(range) (Gy) 
Delivered 
median dose 
(range) (Gy) 
p-value 
GTV-n D98  68.2  
(66.3-70.2) 
68.5  
(63.2-70.7) 
0.007* 68.5  
(66.4-70.7) 
67.7  
(63.2-68.5) 
0.17 
GTV-n D2  72.4  
(71-74.5) 
73.1  
(71.4-75.4) 
<0.001* 73.1  
(71-74.5) 
73  
(71.3-73.2) 
0.72 
NTT max 71.8  
(67.5-75) 
72.7  
(68.4-77.4) 
<0.001* 71.7  
(68.4-75.1) 
71.8  
(72.6-77.4) 
0.26 
Spinal cord max 43.9  
(40.6-45.7) 
44.9  
(41-46.7) 
0.05* 44.6  
(41-45.8) 
45.6  
(44.9-46.7) 
0.06 
Brainstem max 49.1  
(41.5-59.6) 
49.4  
(41.6-59.3) 
0.24 47.8  
(41.6-59.3) 
53.3  
(52-53.7) 
0.07 
Ipsilateral 
parotid gland 
mean 
42.3  
(22.9-65.8) 
43.9  
(25.3-66.6) 
<0.001* 39  
(25.3-66.1) 
63  
(60.2-66.6) 
0.02* 
Contralateral 
parotid gland 
mean 
25.6  
(19.2-40.5) 
25.7  
(19.7-41.7) 
0.001* 24.9  
(19.7-41.7) 
26.4  
(22.2-32.8) 
0.95 
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reducing doses to surrounding OAR in the presence of anatomical change.[7, 
16, 17]  However, ART implementation involves an increased workload for 
clinical staff, including Radiation Therapists, Medical Physicists and 
Radiation Oncologists, and an increased use of departmental resources due 
to the re-planning process.[18, 19]  A substantial financial burden to the 
department may also result due to the costs accompanying re-imaging and 
re-planning.  This highlights the need to identify specific factors that can 
predict the likelihood of re-planning.  A proactive approach, such as the 
predictive models and risk profiles described, allows a more seamless 
integration of ART into the clinical workflow.   
 
Investigations of various external predictors for the need to re-plan, including 
skin separation and positional variation, did not reveal a single anatomical or 
positional variable as a reliable predictor. [20, 21]  In contrast, Capelle and 
colleagues found when assessing ART using helical Tomotherapy in HNSCC 
patients that the best predictors of patients receiving the greatest benefit 
were the degree of weight loss and reduction in neck separation.[22]  Based 
on their results, it was recommended that it would be beneficial to electively 
schedule re-planning prior to the commencement of radiation therapy 
treatment for NPC patients.[22]  Similarly, the triggers used as basic 
thresholds for ART in the study by Chen et al. included dramatic weight loss, 
rapid clinical shrinkage of palpable or visible disease and/or a prolonged 
treatment break.[19]  These results are comparable to those of the current 
study where it was found that N stage, size of the pre-treatment dominant 
node, diagnosis and initial weight were significant factors in the likelihood of 
needing re-planning. 
 
This study also found that NPC patients were more likely to require a re-plan 
in comparison to OPC patients.  This finding is similar to other studies 
investigating the role of ART in NPC patients.[7, 19, 23]  There could be 
numerous reasons explaining this finding.  Yang et al. report that anatomical 
changes such as primary tumour and/or nodal mass shrinkage and weight 
loss, are commonplace with NPC patients receiving radiotherapy.[23]  Chen 
and colleagues also comment that doses delivered to tumour volumes and 
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critical OAR, such as the brainstem and optic structures, are commonly at 
the limit of the prescribed tolerance and ART can be essential in ensuring 
these OAR doses remain acceptable.[19]  In this study, potential overdosing 
of critical OAR such as the optic structures and brachial plexus were the 
primary reason for the treating Radiation Oncologist’s decision to re-plan.  
Consequently, the ART risk profiles have been developed to address OPC 
and NPC patients separately. 
 
All patients who had a re-plan in this study had virally associated disease, 
however as a result; it was unable to be included in the predictive model.  
This could be a reflection of the fact that more than three-quarters of patients 
had virally associated disease.  Despite this, viral status should remain a 
consideration when identifying potential patients for ART as numerous 
studies have reported the increased radioresponsiveness of virally 
associated OPC and NPC.[24-26]  
 
Logistic regression models are now more widely used in health research, 
particularly as a means to predict the risk of events.[27]  Advantages include 
ability to allow the effect of variables and their interactions on the outcome of 
interest to be estimated and the ability to estimate the strength of the 
association between the predictor and the event.[27, 28]  However, logistic 
regression results can be difficult to interpret, reducing the likelihood of its 
clinical use.  Hence, CART analysis and ART risk profiles were developed to 
facilitate ease of clinical implementation.  CART is a tree-building tool, which 
helps determine the most “important” (based on explanatory power) variables 
in a particular dataset, suited to the generation of clinical decision rules.  
Both methods are simple to interpret and account for the inherent variations 
that exist clinically.  The results of both methods are similar and use similar 
threshold points.  The CART diagram is a much simpler approach to 
implement but does not provide the range of options that the risk profiles 
offer.  The choice of approach may be dependent upon departmental 
preference and the magnitude of its HNSCC workload. 
 
In this study, only a small subset of patients was shown to benefit from ART.  
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Although an overall increase was seen between the planned and delivered 
doses, this increase did not result in the GTV-n, spinal cord or brainstem 
being outside clinically acceptable tolerance levels.  The greatest amount of 
difference was seen in the delivered parotid gland dose however, for the 
parotid glands that were being spared, dose still remained clinically 
acceptable.  This differs from the reported 20-30% of patients at a population 
level that may benefit from ART.[29]  Reasons for this may include variations 
in treatment procedures (e.g. target volume and OAR margins used) and 
OAR tolerance doses originally achieved (e.g. 61% patients achieved a 
mean contralateral parotid gland dose less than 26Gy).  However, as patient 
selection for re-planning can be subjective and arbitrary, the focus of this 
study was to identify characteristics that pre-dispose patients to being more 
likely to need ART as opposed to the number of patients who actually 
required ART.   
 
There is variation in the literature regarding dosimetric impact of anatomic 
change on various structures.  Similar to the current study, Wu et al.[30], 
Zhang et al.[31] and Jin et al.[2] report no significant difference between 
planned and delivered doses for the GTV, spinal cord and brainstem.  They 
did observe a significant increase in parotid gland dose and recommended 
re-planning in specific patients to reduce this.  Although the median delivered 
contralateral parotid gland mean dose in this study fell within clinical 
tolerance levels, 3 patients who were not re-planned may have benefited 
from re-planning to reduce the contralateral parotid gland mean to their 
originally planned dose. 
 
In contrast, studies conducted by Hansen et al.[6] and Zhao et al.[7] found 
that changes during treatment significantly decreased the dose to target 
volumes and significantly increased the dose to surrounding OAR such as 
the spinal cord and brainstem.  Schwartz et al. [32] found significant 
underdosing of target volumes and increases to parotid gland doses.  
Although median doses in this study were not significantly different, 
considerable variability can be seen in the range of results obtained.  Multiple 
factors may contribute to this variability including differing time points at 
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which plan recalculation was performed, relative locations of the target 
volumes and OAR and variable beam arrangements and dose gradients.  
This highlights the need to incorporate an individualised approach when 
developing ART guidelines.  As such, the risk profiles described provide a 
guide for clinical decision-making.  This may be particularly pertinent for 
those NPC patients whose OAR are commonly taken to their tolerance levels 
due to the proximity of high dose target volumes. 
 
A limitation of this study is that there was no standard protocol in place 
governing the decision to re-plan.  This instead was at the discretion of the 
treating Radiation Oncologist.  Consequently, the application of these results 
must be viewed with caution due to the differences that may exist between 
Radiation Oncologists in the decision to re-plan.  Also, the predictive models 
and risk profiles were generated using data obtained from only a small 
number of re-planned patients and this may have affected the validity of the 
results.  However, other studies support these findings with smaller numbers 
of patients reported to benefit from ART.[19, 20]  Future prospective studies, 
including the use of deformable registration tools and dose accumulation, are 
required to validate the predictive models and ART risk profiles described for 
OPC and NPC patients undergoing radiotherapy treatment.  Additionally, 
given the radiosensitivity of many head and neck cancers, the ART risk 
profiles presented are likely applicable across a wider range of HNSCC. 
 
Conclusion 
This study developed predictive models and risk profiles for clinical 
implementation to identify OPC or NPC patients that may require ART before 
treatment commencement.  This approach could facilitate effective 
implementation of ART into radiotherapy departments through forward 
planning and appropriate resource allocation. 
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Chapter 7 
The purpose of Chapter 7 was to analyse patients who underwent re-
planning in the prospective study to determine factors that influence the 
timing of re-planning.  This relates to the second objective of this research.  
Information on the optimal timing of re-planning enables a comprehensive 
predictive approach to be developed for clinical implementation. 
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ABSTRACT 
Aim 
Head and neck (H&N) cancer patients can undergo anatomical change 
throughout radiotherapy treatment.  Adaptive radiotherapy (ART) is effective 
in addressing the impact of this change on the planned dose distribution.  
The aim of this study was to identify pre-treatment factors that influence the 
need for and timing of replanning for patients receiving chemoradiotherapy 
for node-positive nasopharyngeal (NPC) and oropharyngeal carcinoma 
(OPC). 
 
Methods  
Of 110 patients enrolled in a prospective H&N ART study, 21 (19%) 
underwent a second planning scan (re-CT) and were included in this review.  
Univariate and multivariate analysis was used to compare those patients who 
were replanned with those that were not.  Factors influencing the timing of 
replanning were assessed including patient and tumour characteristics and 
structure volume details.   
 
Results 
Of the 5 replanned patients, 3 were diagnosed with NPC (p=0.06) and had 
significantly larger initial nodal volumes (median volume 140.3 cc versus 39.1 
cc, p=0.019).  Overall the median time of re-CT was significantly different 
between replanned and non-replanned patients, with replanned patients 
having an earlier re-CT: median fraction 18 versus fraction 23 (p=0.01).  
Specifically, NPC patients who were replanned had a re-CT performed 
earlier than OPC patients (median fraction 11 versus 20).  
 
Conclusions 
For H&N patients with large nodes receiving definitive chemoradiotherapy, 
replanning may be considered at the commencement of week 3 for NPC 
patients and in week 4 of treatment for OPC patients.  This information may 
facilitate a forward planning approach to H&N ART that enables allocation of 
departmental resources prior to treatment commencement. 
Keywords; adaptive, head and neck cancer, radiotherapy  
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Introduction 
Anatomical and tumour changes can occur during chemoradiotherapy for 
head and neck (H&N) cancer.  These include changes in weight, primary 
tumour or nodal disease size and post-operative changes such as oedema.1, 
2 Adaptive radiotherapy (ART), in terms of replanning during treatment, is 
effective in addressing this issue and the potential detrimental impact to the 
planned dose distribution.  This is of particular importance with the routine 
use of intensity modulated radiotherapy (IMRT), volumetric modulated arc 
therapy (VMAT) and Tomotherapy where positional and anatomical variation 
can result in under or over dosing of target volumes and organs at risk (OAR) 
due to the rapid fall-off in dose.3 However, factors that influence replanning 
and their timing within the treatment process remain unclear.  It is important 
to address this issue to both maintain the integrity of the intent of the original 
plan, and for forward planning in order to appropriately allocate departmental 
resources.  Volumetric rate of change of both target volumes and OAR and 
their correlation with the actual dose received by these structures have been 
previously examined.3-6 Limited studies have provided recommendations on 
when replanning should be scheduled.  Improved understanding of influential 
pre-treatment factors is important in developing strategies for practical 
clinical implementation of ART that will benefit radiotherapy department and 
patient.6, 7  
 
The aim of this study was to identify pre-treatment factors that influence the 
need for and timing of replanning for patients receiving chemoradiotherapy 
treatment for node-positive nasopharyngeal (NPC) and oropharyngeal 
squamous cell carcinoma (OPC).  Patients with tumours of these two primary 
sites commonly present with nodal involvement and have a high rate of viral 
association, resulting in a high response rate to radiotherapy.  This 
information will contribute to the development of predictive ART guidelines 
for H&N cancer patients that enable the allocation of departmental resources 
prior to treatment commencement. 
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Materials and Methods 
Patients 
This investigation formed part of a broader prospective study exploring H&N 
ART.  Of the 110 enrolled patients, 21 underwent a second planning 
computed tomography scan (re-CT) during treatment and were included in 
this study.  Patients were recruited from three tertiary radiotherapy 
departments in Brisbane, Australia and commenced treatment between 
October 2013 and December 2014.  This study was approved by the 
Princess Alexandra Hospital, Royal Brisbane and Women’s Hospital and 
Queensland University of Technology Human Research Ethics Committees.  
All patients gave their consent to participate in the study.  Inclusion and 
exclusion criteria have been previously reported.8 Patient demographics, 
tumour characteristics, including pre-treatment size of the largest involved 
node, and treatment details were recorded.  Information regarding the timing 
of the re-CT, weight and structure volume details at planning and time of re-
CT and whether the patient had a replan generated were also recorded. 
 
Treatment planning 
All patients underwent treatment planning as previously described by Brown 
et al.8 Gross tumour volumes (GTV) were outlined with the aid of clinical 
findings and imaging including, as a minimum, contrast-enhanced diagnostic 
CT and hybrid positron-emission tomography-CT (PET-CT) that were co-
registered with planning scans.  Magnetic resonance imaging (MRI) was 
performed in selected cases where greater resolution of soft tissue extension 
of disease was required, such as the base of tongue and NPC.  The GTV 
was expanded by 5 mm isotropically to the high dose clinical target volume 
(CTV), which was edited to exclude air and radiologically uninvolved bone.  
The CTV receiving an intermediate dose also included the high dose CTV, 
areas in close proximity to the primary site considered at higher risk of 
relapse and radiologically equivocal lymph nodes.  The low dose CTV 
included the intermediate dose CTV and elective nodal regions depending on 
the location and extent of primary site involvement, and involved lymph 
nodes.  All CTVs were expanded by 5 mm to respective planning target 
volumes (PTV).   
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Re-CT 
All patients had a daily, pre-treatment cone beam CT (CBCT) or 
megavoltage CT (MVCT) scan taken.  This was used specifically for patient 
set-up to correct for positioning variations between the planning and 
localisation scans.  The imaging tolerance used for positioning was 3 mm 
translation and 3 degrees rotation.  CBCTs and MVCTs were also reviewed 
on a weekly basis by one of four Radiation Therapists to specifically assess 
the need for the patient to undergo a re-CT based on anatomical change.  A 
re-CT was performed if the difference between the planning scan and the 
CBCT was greater than 1 cm at any point of the external contour within the 
treatment area.   
 
Replan assessment 
Initially the original planning CT and the re-CT were fused using rigid 
registration methods according to the region of interest specified by the 
Radiation Oncologist.  Similar to the hybrid technique described by Hansen 
et al.1 the original plan was translated to the re-CT and calculated using the 
original monitor units. The Radiation Oncologist reviewed the plan through 
visual inspection and dose volume histogram (DVH) evaluation.  No 
deformable image registration software was available at the time of the study.  
For all re-CT patients, nodal gross tumour volume (GTV-n) and parotid 
glands were manually re-contoured by the Radiation Oncologist, to record 
volume and dose changes.  These structures were chosen for re-contouring 
as they have been previously reported to undergo considerable volume 
change during radiotherapy.4, 9, 10 The decision to replan a patient was made 
at the discretion of the treating Radiation Oncologist and was based on 
factors including serial OAR, such as the spinal cord or optic structures, 
receiving a higher than acceptable dose or inadequate target volume 
coverage. 
 
Doses received by the GTV-n, non-target tissue (NTT), spinal cord, 
brainstem and parotid glands were recorded from both the original plan and 
the delivered dose plan.  NTT encompassed all tissue in the dataset outside 
the PTV.  The delivered dose plan consisted of the addition of the original 
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plan and the replan assessment, with prescription doses altered to reflect the 
portion of the treatment course to which each plan related. 
 
Statistics 
Univariate and multivariate analyses were used to compare patients whose 
re-CT resulted in generation of a replan with those that did not.  Mann-
Whitney tests11 were used to compare various factors between patients who 
were replanned and those who were not as data were not normally 
distributed.  Tested factors included the fraction the re-CT was performed, 
diagnosis, weight at planning and at re-CT and size of the largest involved 
node at planning and at re-CT.  Bonferroni correction was used when 
appropriate to adjust for multiple testing.  Logistic regression was used to 
model the relationship between requirement for a replan and explanatory 
variables found to be significant in univariate analysis.  Comparison of 
dosimetric factors was conducted between the original treatment plan and 
the delivered dose using the Wilcoxon matched-pairs signed-ranks test.12 
Mann-Whitney tests11 were also used to compare delivered doses between 
patients who had a replan generated and those that did not.  A p-value of ≤ 
0.05 was considered statistically significant.  The analysis was conducted 
using the Stata (version 12.1, StataCorp LP, Texas, USA) program.  
 
Results 
Patients 
Patient characteristics are detailed in Table 1.  All patients were prescribed a 
dose of 70Gy in 35# and received concomitant chemotherapy.  Of the 21 
patients, 15 (71.4%) had a diagnosis of OPC and 6 (28.6%) NPC.  Between 
the planning CT and re-CT, the size of the largest pre-treatment involved 
node reduced by a median of 42.8% with patients experiencing a median of 
approximately 10% weight loss.  The ipsilateral and contralateral parotid 
glands reduced in size by a median of 21.7% and 20.3% respectively.  Five 
(23.8%) patients had a replan generated.  Three replanned patients (60%) 
had a primary diagnosis of NPC.  All replanned patients had virally 
associated disease.  One patient received two re-CTs during treatment with 
the second scan resulting in the generation of a replan.  All patients that 
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underwent replanning only had one new plan produced. 
 
Table 1 Patient characteristics 
 
Characteristic Value (range) 
Gender 
Male 
 
21 
Median age (years) 55 (28-73) 
Diagnosis 
Oropharynx 
Nasopharynx 
 
15 
6 
Viral status 
Positive 
Negative 
 
19 
2 
T stage 
1 
2 
3 
4 
 
4 
5 
7 
5 
N stage 
1 
2 
3 
 
2 
15 
4 
Chemotherapy 
Cisplatin 
Cetuximab 
 
16 
5 
Median fraction of re-CT 22 (10-25) 
Median initial nodal volume (cc) 41.7 (3.9-268.8) 
Median re-CT nodal volume (cc) 21.4 (2.1-168.2) 
Median percentage nodal volume 
regression (%) 
42.8 (27.4-80.1) 
Median initial weight (kg) 101.4 (57-150.9) 
Median re-CT weight (kg) 90.6 (50.3-133) 
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Median percentage weight loss (%) 10.3 (2.5-13.7) 
Median initial ipsilateral parotid 
volume (cc) 
32.7 (18.6-48.9) 
Median re-CT ipsilateral parotid 
volume (cc)  
25.1 (14-48.6) 
Median percentage ipsilateral parotid 
reduction (%) 
21.7 (3.6-51.4) 
Median initial contralateral parotid 
volume (cc) 
32.8 (15.4-52) 
Median re-CT contralateral parotid 
volume (cc)  
24.4 (14.6-47.1) 
Median percentage contralateral 
parotid reduction (%) 
20.3 (13.8-46.4) 
Replan 
No 
Yes 
 
16 
5 
 
 
Patient comparison 
A comparison of patient characteristics for the group that only had a re-CT 
and those that were selected for replanning is displayed in Table 2.  Primary 
diagnosis approached statistical significance in the need for a replan 
(p=0.06).  Replanned patients had significantly larger median initial and re-
CT nodal volumes than those patients who only had a re-CT (p=0.019 and 
p=0.01 respectively).  The median fraction at which the re-CT was performed 
was also significantly different between the two groups with replanned 
patients having a re-CT at an earlier time point (p=0.01).  The median nodal 
volume rate of change was greater for replan patients compared with those 
who only had a re-CT (-3.3 cc/fraction and -0.69cc/fraction respectively) but 
was not statistically significant.  All other characteristics were similar.   
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Table 2 Comparison of characteristics between patients who had a re-
CT only and those who also had a replan 
Characteristic Re-CT only 
(range) 
Re-CT + replan 
(range) 
p-value 
Diagnosis 
  OPC 
  NPC 
 
14 
3 
 
2 
3 
0.06 
Fraction 23 (11-25) 18 (10-21) 0.01* 
Median initial node 
volume (cc) 
33.1 (3.9-140.3) 140.3 (20.9-
268.8) 
0.019* 
Median re-CT node 
volume (cc) 
17.0 (2.1-107.1) 70.9 (20.7-168.2) 0.01* 
Median percentage node 
volume regression (%) 
34.7 (-27.4-80.1) 47.1 (1-56.8) 0.934 
Median node volume 
rate of change 
(cc/fraction) 
-0.69 (-3-0.1) -3.3 (-11.5 to -
0.01) 
0.137 
Median initial weight (kg) 101.4 (67.5-150.9) 101.4 (57-130) 0.814 
Median re-CT weight 
(kg) 
88.5 (59.5-133) 92.7 (50.3-121.4) 0.845 
Median percentage 
weight loss (%) 
11 (-2.5-13.7) 8.6 (6.2-11.8) 0.411 
Median weight rate of 
change (kg/fraction) 
-0.5 (-0.9-0.1) -0.5 (-0.6 to -0.4) 0.667 
Median initial ipsilateral 
parotid gland volume (cc) 
32 (18.6-47.6) 37.8 (21.5-48.9) 0.505 
Median re-CT ipsilateral 
parotid gland volume (cc) 
23.4 (14.2-48.6) 30.9 (14-48.5) 0.611 
Median percentage 
ipsilateral parotid gland 
volume reduction (%) 
23.2 (-3.6-51.4) 17.7 (0.8-34.9) 0.505 
Median initial 
contralateral parotid 
32.5 (15.4-52) 40.3 (25.4-44.5) 0.638 
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gland volume (cc) 
Median re-CT 
contralateral parotid 
gland volume (cc) 
22.9 (14.6-47.1) 29.9 (18.5-42.6) 0.256 
Median percentage 
contralateral parotid 
gland volume reduction 
(%) 
21.9 (-13.8-46.4) 18.6 (0.5-32.8) 0.638 
* indicates statistical significance 
 
Primary diagnosis and initial nodal volume were included in the logistic 
regression model.  Re-CT nodal volume was removed as it highly correlated 
with the initial nodal volume.  This model was found to be significant 
(p=0.003), correctly classifying 85.7% of patients.  The results of post 
estimation testing are displayed in Table 3. 
 
Table 3 Post estimation results for logistic regression model 
 
Item Results 
p-value 0.003 
Pseudo R2 0.5143 
Sensitivity 60% 
Specificity 93.75% 
Positive predictive value 75% 
Negative predictive value 88.24% 
Correctly classified 85.71% 
 
Diagnosis stratification 
The two groups were stratified according to diagnosis.  Replanned patients 
with a diagnosis of NPC had a re-CT performed earlier (median fraction = 11, 
range = 10-18) when compared to OPC patients (median fraction = 20, range 
= 19-21) (Figure 1).  This difference was not statistically significant even after 
adjustment for multiple testing (p=0.08).  The median nodal volume rate of 
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change was greater for replanned patients with a diagnosis of NPC than 
OPC patients (-6.4 cc/fraction and -1.9 cc/fraction respectively) but was not 
statistically significant.  All other characteristics were similar between the 
groups. 
 
 
Figure 1 Box plot demonstrating the median fraction and range the re-
CT was performed per diagnosis.  OPC = oropharyngeal 
carcinoma, NPC = nasopharyngeal carcinoma. 
 
Discussion 
H&N patients undergoing chemoradiotherapy treatment experience changes 
in target and OAR volumes and weight, potentially impacting their planned 
dosimetry.  ART can address these changes, but patient selection and timing 
of intervention are critical issues that require clarification.  This study 
examined ART in node-positive H&N patients with larger nodal volumes 
receiving chemoradiotherapy.  In this cohort, reimaging with the view to 
replan at the beginning of week three of treatment, for NPC and in week four 
for OPC patients, may be considered prior to treatment commencement.  
Optimal scheduling of intervention is important in successful implementation 
of ART as replanning involves both an increased clinical workload and use of 
departmental resources.6   
 
! 139!
This study found that NPC patients were more likely to be replanned when 
compared to OPC patients.  Similar findings have been reported in other 
H&N ART studies.13-15 Chen et al. noted that for NPC patients, tumour 
volume and critical OAR doses are commonly at the limit of their prescribed 
tolerance and replanning can be essential in ensuring these OAR doses 
remain within tolerance.15 It has also been reported that target volume 
shrinkage and weight loss, are more commonplace with NPC patients 
receiving radiotherapy.14 It should also be noted that NPC patients in this 
study had more advanced nodal disease with a median N stage of 3 as 
compared to 2 for OPC patients. 
 
When categorised into patients who were selected for replanning and those 
who were not, replanned patients had significantly larger pre-treatment size 
of the largest involved node.  Replanned patients also had a greater nodal 
volume rate of change although this did not reach statistical significance.  
The effect of nodal volume regression can also be seen in the larger increase 
in delivered dose for the ipsilateral parotid gland compared to the 
contralateral parotid.8 This suggests that size of the pre-treatment largest 
involved node is associated with the need for ART in H&N cancer patients.  
All replanned patients had virally associated disease and as such, could not 
be included in the logistic regression model.  However, this finding does 
suggest that viral status may be an influencing factor in the need to replan.    
 
Formulating a predictive approach to H&N ART based on pre-treatment 
factors is important in facilitating the appropriate allocation of departmental 
resources and promoting a streamlined workflow.  A key component of this 
approach is timing of replanning.  Replanned patients underwent a re-CT 
significantly earlier than those patients who were not replanned, with 
intervention occurring in week four and week five respectively.  Different time 
points that may be optimal for adaptive intervention have been proposed 
(Table 4).16-22 Parotid gland volume change dominates this decision and 
reimaging and replanning is often suggested in the first half of treatment.6 
The results of this study further support these recommendations with the 
majority of replanned patients being reimaged in the first half of treatment.  A 
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timing difference was observed in replanned patients with NPC patients 
typically having a re-CT performed earlier in their treatment.  After 
adjustment for multiple testing this was not found to be statistically significant 
but is considered clinically significant due to the majority of replanned 
patients having NPC.  The reason for this difference is unclear and there is 
little published data regarding this topic.  One explanation could be the 
greater rate of nodal volume regression for NPC patients.   
 
This study identified a small group of patients who required ART.  This is 
reflective of the local Australian context.  In all structures examined in the 21 
patients, delivered dose was greater than planned dose however this 
increase equated to ≤1% in all structures except the ipsilateral parotid gland 
(2.8%) and contralateral parotid gland (3.6%).8  GTV-n coverage remained 
within +/- 105% of the prescribed dose and OAR median doses remained 
less than their prescribed tolerance.  The primary reason to replan was to 
reduce dose to the brachial plexus as the delivered dose was exceeding the 
prescribed tolerance.  This is not a surprising finding considering that the 
majority of replanned patients had NPC and the brachial plexus was taken to 
its tolerance dose in order to maximise the dose delivered to the surrounding 
high dose tumour volume.  No Radiation Oncologist elected to replan based 
only on increase to the parotid gland dose.  Variation exists in the literature 
with regard to the number of patients that may benefit from ART.  In a study 
of 23 patients, Ahn et al 23 found that 15 (65%) of patients required ART.  
Schwartz and colleagues 19 reported that all patients underwent one replan 
and 34.8% patients benefitted from two replans.  In contrast, Chen et al 15 in 
their study of 317 patients reported that 51 (16%) of patients required ART.  
This demonstrates that Australia is more conservative in terms of replan 
frequency in comparison to rates reported in international studies.  Reasons 
for this variation could include: differing CTV to PTV margins used, relative 
locations of target volumes and OAR, differing treatment techniques and 
beam arrangements employed (e.g. step-and-shoot IMRT versus 
Tomotherapy and VMAT)24 as well as differences in the tolerance doses 
specified and originally achieved planned dose for various OAR (e.g. 61% of 
patients in this study achieved a mean contralateral parotid gland dose less 
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than 26Gy).  
 
A limitation of this study was the small number of patients reviewed, 
particularly those that underwent a replan.  A larger prospective study is 
required to validate these findings.  It should also be noted that there is 
potential for variability between Radiation Oncologists in terms of GTV-n 
delineation and decision to replan.  This was not accounted for in the study 
and therefore, the results should be interpreted with a further degree of 
caution. 
 
Conclusion 
For H&N patients with large nodal volumes receiving chemoradiotherapy, it is 
appropriate to consider a re-CT at the commencement of week three for 
patients with NPC and in week four of treatment for OPC patients.  This 
information will facilitate a forward planning ART approach for H&N cancer 
patients that enables allocation of departmental resources prior to treatment 
commencement. 
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Chapter 8 Review of re-planning 
rates 
8.1 Introduction 
Substantial variation exists in the reported percentage of patients that 
undergo reimaging and replanning in H&N ART literature.  Reported 
percentages range anywhere from 0 to 65%.[1, 2]  This is particularly 
apparent when comparing the results of the current study, where 4.5% of 
patients were replanned, with other studies.[3]  It is important to examine and 
understand the reasons for this disparity to place the results of the current 
study in an international context.  If international replanning rates are higher, 
the results of the current work will greatly assist in the systematic evaluation 
of need of ART for H&N cancer patients. 
 
In order to compare the findings of the current study with the international 
data on reimaging and replanning, a comprehensive review of the current 
literature regarding the anatomical and dosimetric changes that can occur 
during H&N radiotherapy and recommendations concerning the use of ART 
was conducted.  Specific focus was placed on patient selection, frequency 
and timing of reimaging, replanning rate and parotid gland dose.  Studies 
were categorised by geographical region and compared to assess their 
relationship to the Australian context, particularly the current study, and to 
provide practical information for the development of ART strategies. 
8.2 Methods 
A literature search was conducted in MEDLINE and Pubmed using the 
following keywords: head and neck AND adaptive AND radiotherapy. 
Additionally, reference lists of papers were investigated to capture relevant 
papers that may have been overlooked in the initial search.  Included papers 
were published between 2006 and 2015.  Studies were excluded from the 
review if they were published in languages other than English, if they were 
only available in abstract form or if there was no volumetric or dosimetric 
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data reported.  Studies were considered eligible for inclusion if they reported 
on the anatomic changes with reference to dosimetric impact in H&N cancer 
patients undergoing radiotherapy. 
 
Demographic data of each study’s patient cohorts, radiotherapy technique, 
frequency and timing of reimaging, anatomical and dosimetric changes and 
rate of replanning, was extracted.  The data from eligible studies was 
combined as well as categorised by international region in order to explore 
potential differences between studies in different areas. 
8.3 Results 
8.3.1 Literature search 
A total of 53 articles were found in the initial literature search of both 
MEDLINE and Pubmed and relevant reference lists.  Of these, 17 articles 
were excluded as they were only available in abstract form or did not report 
information regarding dosimetric impact or replanning.  This resulted in 36 
articles being included in this review. 
8.3.2 Overall review 
Both retrospective (44%) and prospective (56%) studies were reviewed.  
Five large studies were identified with sample sizes ranging from 72-317 
patients.[3-7]  The mean sample size of the remainder of studies was 17 
patients (6-48).  IMRT was the radiotherapy technique employed in more 
than 75% of studies with greater than 50% of patients studied having a 
primary diagnosis of oropharyngeal cancer (OPC).  The remainder of 
patients had nasopharygeal cancer (NPC), oral cavity, laryngeal or 
hypopharyngeal cancers.  Only three studies reported the viral status of 
patients (e.g. positive or negative for the human papillomavirus).[3, 8, 9]  Ten 
studies (27.8%) reported the percentage of patients replanned either in the 
study itself or from the reporting institution.[1-5, 7, 10-13] Increase in parotid 
gland dose was found to be the primary reason for replanning to be 
performed.  The absolute mean parotid gland dose from the original plan was 
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reported in 16 (44%) studies [1-3, 7, 8, 13-23] and the fractional mean 
parotid gland dose was reported in 4 (11%) studies.[6, 10, 24, 25] 
8.3.3 Studies by region 
Studies were categorised into five geographical regions: United States of 
America (11), Europe (10), United Kingdom (UK) (3), Asia (10) and Australia 
(2).  An overview of the studies by geographical region is demonstrated in 
Table 8.1.  Figure 8 . 1 shows mean ipsilateral and contralateral parotid 
gland dose reported in the original plan by geographical region. 
!
Table 8.1 Comparison of H&N ART studies across geographical regions 
Parameter Region USA Europe UK Asia Australia 
Number of studies 11 10 3 10 2 
Mean sample size 
(patients) (range) 
21* (10-48) 
*Excluded 1 
outlier = 317 
12 (6-16) 
*Excluded 2 
outliers = 72 & 94 
15 (10-20) 17* (9-33) 
*Excluded 1 
outlier = 129 
10 & 110 
Main primary 
diagnosis 
OPC Oral cavity, 
larynx, 
hypopharynx 
OPC NPC OPC 
Median age 
(years) (range) 
56 (21-93) 61 (22-87) 54 (36-77) 53 (26-77) 59 (28-77) 
 
Technique 
  IMRT 
  VMAT 
  Tomotherapy 
 
82% 
0 
18% 
 
80% 
0 
20% 
 
100% 
0 
0 
 
70% 
20% 
10% 
 
29% 
61% 
10% 
Prescription dose 70Gy/35# 
(60-74Gy) 
70Gy/35# 
(64-72Gy) 
70Gy/35# 
(65-70Gy) 
70Gy/28# 
(70-76Gy) 
70Gy/35# 
(66-70Gy) 
Chemotherapy concurrent concurrent concurrent concurrent concurrent 
Median CTV-PTV 
margin (cm) 
0.5 0.5 0.3 0.3 0.5 
Mean frequency of 
reimaging (range) 
3* (1-7) 
*2 studies daily 
4* (1-6) 
*1 study daily 
3 (1-6) 2 (1-5) 1 
Mean time point of 
reimaging (#) 
(range) 
20 (11-33) 
or 
Weekly 
(weeks 1-6) 
Weekly 
(weeks 2-5) 
Weekly 
(weeks 2-
5) 
20 (15-35) 22 (10-25) 
Mean replanning 
rate (%) (range) 
30 (9-65) 20 0 & 33.3 66.7 0 & 4.5 
Mean weight loss 
(%) (range) 
7.7 (3.3-11.2) 4.7 (2.6-6.7) 6.4 (2-9.7) 7.3 (4.6-9.3) 6.7  
(3-10.3) 
Mean PG volume 
loss (%) (range) 
  IPG 
  CPG 
 
 
31.9 
26.4 
 
 
35.6 (30-43) 
35.3 (30-40) 
 
 
28 
24 
 
 
6.7 
1.2 
 
 
21.1 
22 
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  LPG 
  RPG 
17.8 (5-27) 
14.7 (5-24) 
21.9 (2-42) 
29.6 (18-41) 
NR 
NR 
30 (21-41) 
28.7 (20-38) 
NR 
NR 
Mean increase in 
SC max dose (%) 
(range) 
6.7 (2.2-9.3) 2.7 (1.5-4.3) 4 (2.5-5.4) 6.3  
(0.4-14.5) 
1.7  
(1.1-2.3) 
Average planned 
mean PG dose 
(Gy) (range) 
  IPG 
  CPG 
  LPG 
  RPG 
 
 
 
38.8 (38-40) 
30.6 (28-33) 
29.5 (29-30) 
30 (29-31) 
 
 
 
24.9 (19-30) 
21.4 (17-26) 
26 
26.5 
 
 
 
38.4 
26 
NR 
NR 
 
 
 
53.8 
29.9 
38.9 (28-52) 
38.5 (28-52) 
 
 
 
42.3 
25.6 
NR 
NR 
Average PG mean 
dose increase (%) 
(range) 
  IPG 
  CPG 
  LPG 
  RPG 
 
 
 
4 
3 
8.4 (3-12) 
5.9 (0.2-9) 
 
 
 
8.4 (4-13) 
12.4 (4-22) 
4.3 
10.2 
 
 
 
4.6  
4 
NR 
NR 
 
 
 
9.1 
31.6 
9.5 (3-12) 
9.9 (2-19) 
 
 
 
3.8 
0.4 
NR 
NR 
 
USA – United States of America; UK – United Kingdom 
OPC – Oropharygneal cancer; NPC – nasopharyngeal cancer 
IMRT – Intensity Modulated Radiation Therapy; VMAT – Volumetric 
Modulated Arc Therapy 
CTV – Clinical Target Volume; PTV – Planning Target Volume 
PG – Parotid gland; IPG – Ipsilateral parotid gland; CPG – Contralateral 
parotid gland; LPG – Left parotid gland; RPG – Right parotid gland 
SC – Spinal cord 
NR – not reported 
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Figure 8 . 1 Mean parotid gland dose achieved in the original plan for the 
ipsilateral (IPG) and contralateral parotid glands (CPG) by geographical 
region.  USA – United States of America; UK – United Kingdom 
 1.  Hunter et al. [15]  5.  Bhide et al. [20] 
 2.  Ricchetti et al. [8]  6.  Cheng et al. [21] 
 3.  Castadot et al. [17]  7.  Brown et al. [3] 
 4.  Cozzolino et al. [19] 
 
8.3.4 United States of America 
Eleven (30%) American studies were examined.[2, 4, 8-10, 14, 15, 24, 26-
28]   
8.3.4.1 Patient selection 
The majority of patients studied had a primary diagnosis of OPC with the 
remainder of patients having diagnoses of NPC, hypopharyngeal or 
laryngeal cancer.  Both definitively treated and post-operative patients were 
included in three studies.[2, 4, 24]  The largest study identified had a sample 
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size of 317 patients [4] with the remainder having a mean sample size of 21 
patients (range = 10-48). The median prescription dose employed was 70Gy 
delivered in 35 fractions with the vast majority of patients being treated with 
IMRT.   
8.3.4.2 Frequency and timing of reimaging and replanning rate 
Reimaging was undertaken on average three times during treatment with 
three studies performing reimaging on a weekly basis[8, 15, 27] and two 
studies assessing dosimetric impact on daily in-room imaging scans.[14, 26]  
The majority of studies reimaged patients according to the study protocol.  
One study only reimaged patients if clinicians judged that the patient had an 
ill-fitting mask or had experienced considerable weight loss or tumour 
shrinkage.[10]  Three (27%) studies reported the percentage of patients 
replanned either in their study or at their institution.[2, 4, 10]  Considerable 
variation was noted: 9% [10], 16% [4] and 65%.[2]  The triggers for 
replanning in these three studies were either OAR tolerance doses exceeded 
or inadequate tumour volume coverage.  In the remainder of studies, 
replanning was performed for research purposes only and not for clinical 
implementation.  
8.3.4.3 Parotid gland dose 
Six (54%) studies reported absolute mean parotid dose achieved in the 
original treatment plan[2, 8, 10, 14, 15, 24] with two studies reporting this 
dose as ipsilateral and contralateral mean parotid gland dose.[8, 15]  The 
reported average increase in mean parotid gland dose without replanning 
was 4% and 3% for the ipsilateral and contralateral parotid glands 
respectively and 8.4% and 5.9% for the left and right parotid glands 
respectively. 
8.3.4.4 Overall findings 
In terms of replanning, American studies reported large variation between 
patients with regards to the dosimetric impact of anatomical change and as 
such, ART was only of benefit in selected cases.[4, 8]  ART was not found to 
be of benefit in the post-operative H&N patient setting.[24] 
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8.3.5 Europe 
A total of 10 (28%) of studies originated from European institutions.[5, 6, 11, 
16-19, 29-31]   
8.3.5.1 Patient selection 
The majority of patients had primary diagnoses of laryngeal, hypopharyngeal 
or oral cavity cancer with the remainder OPC or NPC.  A large proportion of 
patients included in European studies received post-operative radiotherapy.  
Two larger studies reported sample sizes of 72 [5] and 94 [6] patients, with 
the remainder of studies having a mean sample size of 12 patients (range = 
6-16).  The median prescription dose used was 70Gy in 35# however, due to 
the inclusion of post-operative patients in many studies, 66Gy in 33 fractions 
was also reported.  Eight studies (80%) employed IMRT techniques whilst 
two studies (20%) utilised Tomotherapy.[6, 17]   
8.3.5.2 Frequency and timing of reimaging and replanning rate 
The mean frequency of reimaging was four times during treatment, most 
often occurring on a weekly basis between weeks two and five.  One study 
assessed dosimetric impact on daily cone beam computed tomography 
(CBCT) scans.[31]  The majority of studies reimaged patients as per the 
study protocol with two studies reimaging patients if their mask was ill-fitting 
or soft tissue changes greater than 0.5cm were observed on CBCT.[5, 6]  
Jensen et al[5] and Reali et al[11] reported similar percentages of patients 
replanned of approximately 20%.  Two studies replanned patients based on 
overdosing of OAR or inadequate tumour volume coverage [5, 6] with the 
remainder of studies replanning patients for research purposes only. 
8.3.5.3 Parotid gland dose 
Six (60%) studies reported the mean parotid gland dose achieved in the 
original plan [16-19, 29, 30] with three studies reporting this dose as an 
ipsilateral and contralateral mean parotid gland dose.[16, 17, 19]  The 
average increase in mean parotid gland dose was 8.4% and 12.4% for 
studies reporting the ipsilateral and contralateral parotid glands respectively 
and 4.3% and 10.2% for studies reporting the left and right parotid glands 
respectively. 
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8.3.5.4 Overall findings 
The overall observation regarding replanning made by European studies was 
the high variation noted amongst individual patients resulting in ART 
benefiting only a selected group of patients.  Patients identified as being at 
high-risk of requiring ART were NPC patients with bilateral neck nodes and 
those patients in whom the surrounding planned OAR doses were close to 
their specified tolerances in the original treatment plan. 
 
8.3.6 United Kingdom 
8.3.6.1 Patient selection 
There were three studies (8%) reported from UK institutions [1, 12, 20] with 
the majority of patients having a primary diagnosis of OPC then NPC or 
hypopharyngeal cancer.  The mean sample size was 15 patients (10-20).  
The range of prescription doses employed was 65-70Gy in 30 to 35 fractions 
with all three studies utilising IMRT as their treatment technique.   
8.3.6.2 Frequency and timing of reimaging and replanning rate 
Two studies reimaged their patients on a weekly basis[1, 20] with one study 
reimaging their patients once during treatment.[12]  Patients were reimaged 
as per each study’s protocol.  Vastly different replanning rates were reported 
for the two studies.  Ho et al[1] found that no patients required replanning in 
their cohort whereas Yip et al[12] reported that 33% of patients in their study 
were replanned.  Reported triggers for replanning were OAR dose exceeding 
tolerance, weight loss or excessive set up uncertainty.   
8.3.6.3 Parotid gland dose 
Two studies reported the mean ipsilateral and contralateral parotid gland 
dose achieved in the original plan with an average increase in mean dose of 
4.6% and 4% for the ipsilateral and contralateral parotid glands 
respectively.[1, 20] 
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8.3.6.4 Overall findings 
Studies from the UK concluded that ART was not routinely required in the 
H&N cancer patient population and its use is only required in appropriate 
cases. 
 
8.3.7 Asia 
A total of 10 studies (28%) were identified from Asian institutions.[7, 21-23, 
25, 32-36]   
8.3.7.1 Patient selection 
One large study[7], with 129 patients, was identified with a mean sample size 
of 17 for the remaining studies (9-33).  The overwhelming majority (96.5%) of 
patients were reported to have a primary diagnosis of NPC.  The median 
prescription dose reported was 70Gy in 28 fractions with prescription doses 
as high as 76Gy also being employed.  The majority of patients were treated 
with IMRT.   
8.3.7.2 Frequency and timing of reimaging and replanning rate 
Patients were reimaged on average twice during their treatment with this 
occurring at weeks three and five of treatment.  Two studies reimaged their 
patients on a weekly basis between weeks one and five of treatment.[33, 35]  
Patients in all studies were imaged as per the study protocol.  Yang et al. 
was the only study to report the percentage of replanned patients (66.7%).[7]  
In two studies, the trigger for replanning was inadequate tumour volume 
coverage or excessive OAR dose [21, 25] with the remainder of studies 
replanning for research purposes only.  
8.3.7.3 Parotid gland dose 
Six studies (60%) reported the mean parotid dose achieved in the original 
plan [7, 22, 23, 34] with only two of these reporting it as mean ipsilateral and 
contralateral parotid gland dose.[21, 25]  The average increase in mean 
parotid gland dose was 9.1% and 31.6% for those studies that reported 
ipsilateral and contralateral parotid glands respectively, and 9.5% and 9.9% 
for the left and right parotid glands respectively. 
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8.3.7.4 Overall findings 
Overall, studies from Asia found that replanning was of particular importance 
for patients with a primary diagnosis of NPC.  Cheng et al.[21] and Jin et 
al.[33] both recommended that replanning be scheduled for NPC patients 
after 30Gy of treatment and Fung et al.[36] recommended that two replans 
are required for NPC patients.  
 
8.3.8 Australia 
Two studies (5.6%) were identified from Australia.[3, 13]   
8.3.8.1 Patient selection 
The two studies were contrasting in sample size.  These were the study 
reported in this thesis [3] involving 110 patients and the study by Height et 
al.[13] involving 10 patients.  The majority of patients studied had a primary 
diagnosis of OPC with NPC patients making up the remainder of patients.  
The median prescription dose employed in both studies was 70Gy in 35 
fractions.  Variation existed in the treatment techniques used with patients 
being treated with IMRT, VMAT, Tomotherapy and conformal boosts.   
8.3.8.2 Frequency and timing of reimaging and replanning rate 
Reimaging was performed once during treatment in both studies with this 
occurring in week five of treatment.  In one study, reimaging was performed 
in accordance with study protocol [13] with the other study reimaging patients 
if the difference between the skin surface on the planning and treatment 
verification scans was greater than 1cm.[3]  Brown et al was the only study to 
report the percentage of patients replanned at 4.5%.[3]  Replanning was 
performed at the discretion of the Radiation Oncologist with OAR exceeding 
their tolerance dose being the primary trigger to replan.   
8.3.8.3 Parotid gland dose 
Both studies reported the mean parotid gland dose achieved in the original 
plan with both studies finding a less than 4% increase in the ipsilateral and 
contralateral parotid gland mean dose. 
! 159!
8.3.8.4 Overall findings 
Despite difference in sample size, both Australian studies found a limited 
need for ART in their H&N patient cohorts, with ART only being of benefit in 
selected patients. 
8.4 Discussion 
Replanning rates and ART protocols reported in various international studies 
were evaluated in order to compare with the findings of the current study.  As 
the replanning rate found in the current work was low, it was important to 
place this in an international context and determine whether this rate was 
comparable to other centres where different H&N ART protocols may have 
been implemented.  The purpose of this was to demonstrate the applicability 
of the predictive approach developed in the current study to areas where 
higher replanning rates are reported.  To achieve this, anatomical and 
dosimetric changes reported in H&N patients during treatment with specific 
reference to the percentage of patients replanned were examined.  Studies 
were compared by geographical region to identify differences in replanning 
protocols.  Considerable heterogeneity was found amongst studies including 
study design, differences in frequency and timing of reimaging, analyses 
performed and reporting making direct comparison difficult.  Two primary 
reasons for reimaging were identified: 
• As per study protocol 
• Observed weight loss, tumour regression or ill-fitting mask 
Similarly, two main reasons for replanning were identified: 
• All patients replanned as per study protocol to assess volumetric 
and/or dosimetric impact 
• OAR exceeding tolerance dose or inadequate PTV coverage 
 
In terms of replanning percentage, considerable variation existed between 
and within geographical areas with the majority of international studies 
reporting much higher replanning rates than Australian studies.  European 
and American studies had similar average replanning percentages of 20% 
and 30% respectively (Table 8.1).  However, within American studies there 
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was a broad range of results with Hansen et al.[10] noting that approximately 
9% of patients were replanned in their institution and Ahn et al.[2] finding that 
65% of patients benefitted from ART in their study.  There are three primary 
factors that may contribute to this vast difference: differences in reimaging 
frequency, differences in reimaging protocol and differences in the actual 
replanning percentage reported.  Ahn et al. reimaged all patients three times 
during their treatment.[2]  In contrast, Hansen et al. only reimaged those 
patients in whom clinicians observed considerable weight loss, tumour 
regression or had an ill-fitting mask, reimaging patients once during 
treatment.[10]  Whereas Ahn et al. reported the replanning percentage from 
their study, Hansen et al. reported the replanning percentage from their 
institution in general, not specifically from their study.  Studies from Asia 
reported a much higher replanning percentage than any other region with 
approximately 67% of patients requiring ART.  However it is important to 
note that replanning percentage was only reported by one Asian study.  The 
two UK studies reported very different replanning rates ranging from 0% [1] 
to 33%.[12].  Differences in reimaging frequency (six times versus once) and 
replanning approach (weight loss and setup uncertainty versus OAR 
exceeding tolerance dose) were the primary reasons for this difference in 
results.  The findings of Ho et al.[1] are very similar to those reported from 
the Australian cohorts, where much lower replanning percentages were 
reported, up to 4.5%.[3]  The potential reasons for this variation across the 
international spectrum are complex and varied and will be explored in the 
following paragraphs.   
 
There was also variation in patient cohorts (Table 8.1).  Studies from 
Australia primarily focused on the OPC patient population whereas studies 
from other regions included a more heterogeneous patient group.  
Unsurprisingly, the focus of studies from Asia was NPC patients whereas 
European studies included a much broader range of mucosal H&N cancers 
including those receiving post-operative radiotherapy.  Location and extent of 
the high dose volume can have a considerable impact on the anatomical and 
dosimetric changes H&N patients’ experience.  This includes factors such as 
parotid gland dose increase, a primary trigger for ART, and weight loss.  This 
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in turn can have a great effect on the percentage of patients requiring 
replanning.  For example, Cheng et al.[21] reported a 9.9% and 34.4% 
increase in the mean ipsilateral and contralateral parotid gland dose, a 
patient population that consisted only of NPC patients who can have 
extensive areas of high dose volume.[37]  Comparatively, the two Australian 
studies with patient populations primarily made up of OPC patients, reported 
increases of less than 4% in the mean ipsilateral and contralateral parotid 
gland doses.[3, 13] 
 
Parotid glands and spinal cord were the most consistently reported OAR.  In 
the majority of studies, increase in spinal cord maximum dose did not push 
this dose above its specified tolerance (Table 8.1).  Therefore patients were 
not replanned based on this factor.  Increase in the mean parotid gland dose 
was identified as the primary catalyst for ART.  The way in which the parotid 
gland dose is reported can have a substantial effect on the actual reported 
dose to these structures depending on their proximity to the high dose 
volume.  Parotid gland dose was reported as left and right parotid gland dose 
in 34.8% of studies, ipsilateral and contralateral parotid gland dose in 47.8% 
and combined parotid gland dose in 17.4% of studies.  This made true 
comparison of parotid gland doses somewhat difficult.  This variation was 
coupled with the differences in the actual dose reported.  Although the 
majority of studies reported mean parotid gland dose, two studies reported 
the V26Gy value[13, 16] and one study reported the median dose.[21]  
Despite these disparities, there were noteworthy differences between 
geographical areas in the planned mean dose reported for the spared parotid 
gland.  Studies from the UK and Australia reported similar planned mean 
contralateral parotid gland doses of approximately 26Gy.  Comparatively, 
American and Asian studies reported higher planned mean doses of 
approximately 30Gy and European studies reported lower planned mean 
parotid gland doses (Table 8.1).  Higher planned mean parotid gland dose 
has been shown to correlate with increased parotid gland volume loss 
through medial movement of the lateral border.[38]  This means that small 
changes, as a result of the parotid glands moving closer to the high dose 
region, are of greater consequence to the delivered mean dose placing them 
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over tolerance and triggering the need for ART.  This highlights the benefit of 
spending time in the planning stage to minimise parotid gland dose to as low 
as possible without compromising tumour volume coverage.  Minimising 
parotid gland dose at the planning stage may potentially reduce the need to 
replan during treatment as a greater ‘buffer’ is created between the planned 
and tolerance doses.  Consequently, the time and resource usage 
associated with the ART process may be reduced, benefitting radiotherapy 
departments.  
 
The relative effect of small changes is demonstrated when examining the 
percentage increase in the mean parotid gland dose per geographical region.  
America, UK and Australia reported similar percentage increases in mean 
parotid gland dose of approximately 4% (Table 8.1).  However, Australia and 
the UK report a considerably lower average rate of replanning than the 
American study average (average 4% and 17% versus 30%).  This could in 
part be attributed to the higher planned mean spared parotid gland dose 
achieved in the American studies in comparison to Australia and the UK 
(approximately 30Gy versus 26Gy).  The consequence of a higher planned 
mean spared parotid gland dose means that small changes, anatomically 
and dosimetrically, have a greater impact resulting in the need to replan. 
 
The difference in ART percentages reported was compounded by the 
extensive variation noted in the timing and frequency of the reimaging 
performed (Table 8.1).  This variation was seen both when comparing all 
studies and between studies within any given geographical region.  
Frequency of reimaging/replanning ranged from once during treatment to 
replanning on daily in-room treatment verification scans.  Aside from those 
studies employing daily replanning, the timing of reimaging ranged from 
fraction 11 to fraction 35, with a proportion of studies reimaging and 
replanning on a weekly basis.  These differences have the potential to 
greatly impact both the dosimetric and anatomical changes reported and 
contribute to comparison difficulties.  The other issue highlighted is the 
current lack of consensus on the optimal frequency and timing of ART.  
Future prospective studies are required to build on the results in the literature 
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to clarify this aspect of ART, taking into account the increased workload 
associated with ART.[39]   
 
Another important difference to note is the variation in reimaging and 
replanning approach adopted, particularly in comparison to the current study.  
The majority of studies (56%) adopted a theoretical approach, reimaging and 
replanning all patients for the purposes of investigating various aspects of 
ART including volumetric and dosimetric impact, replanning thresholds and 
ART strategies.  No generated replans in these studies were implemented 
clinically.  In contrast, the foundations of the current study were based on a 
clinical approach: reimaging patients when an anatomical change of greater 
than 1cm was observed on daily CBCT and replanning when the Radiation 
Oncologist determined a clinical need, primarily relating to OAR overdose.  
As such, the smaller replan rate reported in the current study is considered 
more reflective of the clinical scenario.  This raises the issue of the true 
clinical benefit of ART, an issue that is, as yet, to be extensively explored in 
literature.  Although not the primary purpose of this review, a number of the 
included studies did address the clinical benefit of ART.  Results of two 
studies suggested an improvement in loco-regional control associated with 
the use of ART in appropriately selected patients, particularly in the NPC 
population.[4, 7]  Yang et al. also reported a positive impact on global quality 
of life for NPC patients that had been replanned.[7]  In contrast, Hunter et al. 
reported that ART is unlikely to gain measurable improvement in salivary 
output in most cases due to the substantial reduction in mean parotid gland 
dose that would need to be achieved in the replan (approximately 4Gy).[15]  
This highlights the need for more well-designed prospective studies 
investigating the clinical benefits associated with ART.  It is essential that the 
potential clinical benefits of ART are well defined so they can be 
appropriately balanced against the considerable time and resource 
investment required for ART.  This information will enhance the predictive 
approach described in this work, more accurately targeting those H&N 
patients who will most benefit from ART. 
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Despite the substantial differences found amongst reviewed studies, 
common themes existed in the recommendations and conclusions made.  
The majority of studies found that there was considerable individual variation 
amongst H&N patients.  Consequently, it was recommended that ART is only 
suitable for selected patients, not employed for routine clinical use for the 
whole H&N patient group.  The exception to this was NPC patients who were 
found to have an increased likelihood of requiring ART.  Multiple studies 
recommended reimaging be performed around 30Gy or week three of 
treatment with the view to replan these patients at this point.[21, 33, 34]  In 
addition to a NPC diagnosis, having OAR doses that were close to tolerance 
in the planning phase was another factor of influence in the requirement for 
ART for H&N patients.  Despite the difference in replanning percentage 
between the current study [3] and many others included in this review, the 
conclusions and recommendations of all studies align, adding credence to 
the findings of the current study.  This also emphasises a key finding of the 
current study: despite the initial hypothesis that ART would play a 
considerable role in definitive H&N radiotherapy, the reality is that it is only 
appropriate for use in properly selected cases.  Additionally, the ability to 
have improved predictive capacity at the outset of treatment would be a 
distinct advantage as well as a time and cost saver. 
 
A limitation of this review was the inability to conduct a meta-analysis due to 
vast differences in study design, analysis methods and reported quantities.  
This limitation has been found in similar reviews and contributes to the strong 
argument in favour of systematic reviews in these areas.[39]  Another 
important point to acknowledge is the small sample sizes included in the 
majority of studies.  Aside from five studies with patient cohorts of greater 
than 70 patients, the remainder of studies had an average sample size of 17 
patients.  These smaller patient cohorts make the translation of 
recommendations and results to the general clinical situation more difficult.  
However, as discussed, some common recommendations were discovered 
amongst all studies, regardless of sample size.  Nonetheless, this does 
highlight the need for quality, larger prospective studies in the area of H&N 
ART. 
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8.5 Conclusion 
The reported percentage of patients replanned in Australian studies is 
considerably less than that reported in other international studies.  The 
reasons for this difference are varied and complex including: variation in 
diagnoses studied, variation in study design, analyses performed, quantities 
reported and variation in planned mean dose of the spared parotid gland.  
Despite this heterogeneity, the importance of patient selection for ART and 
the recognition of NPC patients and patients with more extensive disease 
being at higher risk of requiring ART were common amongst all reviewed 
studies.  More well designed prospective studies with large patient cohorts 
are required in the area of H&N ART to provide improved clarification and 
knowledge of optimal ART strategies for this patient group. 
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Chapter 9 Discussion 
9.1 Introduction 
The overarching objective of this thesis was to prospectively identify patients 
receiving chemoradiotherapy treatment for locally advanced OPC and NPC 
who would be most likely to require ART.  The aim was to identify factors that 
predispose OPC and NPC patients to require ART.  The primary endpoint of 
the study was to develop a predictive model and risk profiles that could be 
implemented clinically.  This study provided a novel approach to H&N ART, 
the first of its kind, facilitating the effective implementation of ART into 
radiotherapy departments across Australia and internationally. 
   
The chapter will review and discuss the major findings and contributions of 
this research to the current literature and their significance in the context of 
the national and international setting.  Future directions for this research will 
also be discussed. 
9.2 Key findings 
The key finding of this research was the identification of diagnosis, pre-
treatment size of the largest involved node and N stage as factors that 
predispose OPC and NPC patients to being more likely to require ART.  
Three risk profiles were developed based on predictive modelling.  In order 
to gain most benefit, it was found that re-planning should be considered at 
the commencement of week three for patients with NPC and in week four of 
treatment for OPC patients.  This research also highlighted an important fact: 
despite the initial hypothesis that ART would play a major role in H&N cancer 
radiotherapy treatment due to the nature of the highly conformal treatment 
techniques employed and the anatomical changes these patients tend to 
experience, ART is in fact only appropriate for selected H&N patients.  
 
There is little consensus in literature regarding factors that may predict 
patients who require ART.  Some studies have reported that there are no 
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reliable predictors for the need for ART [1, 2] whereas others have 
suggested weight loss and tumour regression may be useful predictive 
factors.[3, 4]  A retrospective study was conducted to investigate potential 
predictive factors in a group of virally associated OPC and NPC, the results 
of which are presented in Chapters 4 and 5.  It was found that pre-treatment 
size of the largest involved node was the primary predictive factor.  This was 
consistent with other studies that report patients with larger tumour volumes 
experiencing greater visible tumour regression necessitating re-planning.[4, 
5]  When investigating the dosimetric impact of any changes that occurred in 
both the tumour volumes and surrounding OAR, it was found that 
surrounding OAR, particularly the parotid glands, were impacted the most by 
anatomical and tumour changes.   
 
This retrospective phase was the largest known study of this kind conducted 
in Australia.  It represents a unique and novel approach to analysing 
reimaging and replanning data to determine those factors that can be used 
to predict patients that would benefit most from ART.  Results from the 
retrospective phase of this study showed that it could be broadened to 
include patients who do not have virally mediated disease, as all H&N cancer 
patients have the potential to experience anatomical and tumour changes.  
The eligibility criteria for the prospective study were expanded to include all 
patients receiving curative chemoradiotherapy treatment for H&N cancer. 
 
The findings from Chapter 6 demonstrated that pre-treatment size of the 
largest involved node, N stage and initial weight were predictive factors.  
Interestingly, results presented in both Chapters 6 and 7 found diagnosis to 
be a statistically and clinically significant factor, both as a predictor for ART in 
regards to the timing of re-planning.  No clear reason for this difference 
between OPC and NPC patients was found.  It is hypothesised that this may 
be related to the faster rate of nodal disease change noted between OPC 
and NPC patients.[6]  This finding is pertinent for patients with NPC as doses 
delivered to critical OAR, such as the brainstem and optic structures, are 
commonly at the limit of the prescribed tolerance and appropriately timed 
ART can be essential in ensuring these OAR doses remain acceptable.[4, 6]  
! 173!
It is also relevant to note that in this study, the reason for re-planning in the 
majority of cases was to reduce the dose to critical OAR such as the brachial 
plexus and brainstem and not to QoL structures such as the parotid glands 
as has been reported in other studies. 
 
Viral status was not found to be a significant factor in predicting ART need as 
all re-planned patients had virally associated disease.  This was a result of all 
re-planned patients having virally associated disease.  More than 75% of the 
patients in this prospective study had virally associated disease, reflective of 
the substantial shift in the H&N patient demographic.  Therefore it is still an 
important element to consider when identifying patients that may be more 
likely to require a re-plan due to the known improved prognosis and survival 
of this demographic.      
9.3 International context 
Dosimetric analysis demonstrated that only 4.5% of patients in this cohort 
required ART.  This is a relatively small percentage in comparison to 
internationally published data that reports 20-30% of H&N patients requiring 
ART at a population level.[7]  In Chapter 8 the potential reasons for this 
difference were explored and were found to be varied and complex.  
Considerable heterogeneity was found between studies with inconsistencies 
in study design, frequency and timing of re-imaging, analyses performed and 
reporting.  There were also differences between protocols governing re-
imaging and re-planning.  The chief motivation for re-planning in this study 
was the brachial plexus exceeding tolerance.  This contrasted with the 
majority of published studies that report reduction in parotid gland mean 
dose as the primary reason for re-planning.[8, 9]  This was not found to be as 
critical in the current study due to the spared parotid gland mean dose 
achieved in the original plan being less than the specified tolerance (61% 
patients in this study achieved a spared parotid gland mean dose less than 
26Gy).  This emphasises the benefits of minimising the dose to surrounding 
OAR, such as the parotid glands, as much as possible in the original 
treatment plan whilst still achieving target volume coverage.  It is pertinent to 
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stress that the focus of Chapter 6 was to determine characteristics that 
predispose patients to being more likely to require ART as opposed to the 
number of patients who actually received ART.  This was a deliberate 
decision as it is well recognised that patient selection for ART is subjective 
and arbitrary and can depend on the opinion of the treating Radiation 
Oncologist.  Despite the differences found between studies investigating 
H&N ART, the findings of Chapter 8 also revealed similarities in the 
recommendations made by all of these studies regarding ART: the 
importance of patient selection in H&N ART due to the extensive variation 
found between individual patients and the recognition of NPC patients and 
patients with more extensive disease being a high risk group for ART.  It also 
highlighted the need for more well designed prospective studies with large 
patient cohorts, a clinical focus and consistent reporting in the area of H&N 
ART to provide improved clarification and knowledge of optimal strategies. 
 
Predictive modelling of ART provides a number of advantages even when 
the numbers of patients actually requiring it are low.  It allows the effect of 
patient variables and their interactions on the need for re-planning as well as 
the strength of these associations to be estimated.  To demonstrate the utility 
of logistic regression in developing H&N ART predictive models, regardless 
of the magnitude of patients involved, logistic regression analysis was 
repeated on all patients who underwent a second planning scan, making the 
assumption that this scenario always necessitates re-planning. (Appendix 1)  
This increased the theoretical re-planning rate to 19.1%.  In the original 
analysis, nodal disease stage, pre-treatment size of the largest node, 
diagnosis (p<0.01) and initial weight (categorised in 2 groups) (p<0.07) were 
identified as significant for inclusion in the logistic regression model for 
predicting the need to re-plan.  When the percentage of patients re-planned 
was increased, nodal disease stage (p=0.06), pre-treatment size of the 
largest node, diagnosis, initial weight and percentage weight change 
(p<0.01) were identified as significant for inclusion in the logistic regression 
model.  The similarities in the factors identified suggest that this approach is 
useful and sufficiently robust to utilise in varying H&N RT environments.  This 
may have particular importance to international RT departments, which have 
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reported greater replan percentages in comparison to Australia, and 
therefore have the potential to experience greater impact from a predictive 
approach. 
9.4 Impact on radiotherapy workflow 
Development of predictive guidelines enables implementation of a proactive 
approach to patient response to treatment.  This means that the necessary 
steps for adaptive intervention can be factored in from the outset of a 
patient’s treatment, resulting in improved efficiency and efficacy in the 
radiotherapy workflow. (Figure 9. 1)  Predictive factors and risk profiles 
identifying OPC or NPC patients that are more likely to require ART can have 
a substantial clinical impact through this forward planning approach and 
appropriate resource allocation.  Figure 9.1 shows the impact of a predictive 
approach on radiotherapy workflow.   
 
 
Figure 9. 1  Flow diagram demonstrating the impact on radiotherapy 
workflow of the predictive approach !
Based on local experience, the re-imaging and re-planning process can 
require an additional 8 to 10 hours of Radiation Therapist and Medical 
Physicist staff time.  Another hour of treatment machine time is required for 
quality assurance checking.  Additionally, the re-planning process is required 
to occur in a shorter timeframe than the original plan (one week or less 
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versus 2 weeks) due to the need to clinically implement the re-plan as soon 
as possible.  These additional time requirements are not currently factored 
into the day-to-day workflow as is demonstrated in Figure 9. 2.  This results 
in staff being required to do overtime to produce the re-plan in the clinically 
necessary timeframe and can lead to increased stress felt by staff.  As a 
consequence, the risk of errors occurring in the re-planning process is 
heightened.  The ability to predict those patients requiting ART would 
facilitate more judicious use of time and resources.  These can be factored 
into the departmental workflow at the beginning of treatment as opposed to 
the current more ad hoc allocation.  This should considerably reduce the 
need for staff to do unscheduled overtime to re-plan these patients and will 
also aid in reducing staff stress, subsequently minimising the risk of errors 
occurring, benefitting both patient and staff.[10]    
 
 
Figure 9. 2  Bar graph demonstrating the increased patient workload for a 
Radiation Therapist, above standard working hours, required under the 
previous ART workflow 
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9.5 Potential economic benefits 
There are also potential departmental economic benefits following on from 
adoption of this forward planning approach.  Although a cost benefit analysis 
was outside the scope of this study, the potential cost savings associated 
with the forward planning H&N ART approach can be postulated.  These 
include the ability to more accurately identify patients likely to require ART 
and potentially reduce the number of patients undergoing reimaging 
unnecessarily because the resultant dosimetric impact does not warrant re-
planning.   Of the 21 patients that underwent re-imaging in Chapter 6, only 6 
were re-planned.  This means that the more than 75% who did not have a re-
plan incurred extra departmental cost associated with the unnecessary re-
imaging.  Based on these results and using local re-imaging cost data, 
implementation of the predictive approach developed in this study has the 
potential to substantially reduce re-imaging.  There are two key benefits.  
Firstly, for patients, as they are not being subjected to unnecessary radiation.  
Secondly, for departments, in the more judicious use of their resources, both 
in terms of equipment and staff time.  This is a pertinent finding in the local 
and broader Australian context due to smaller percentage of patients 
undergoing re-planning. 
 
Savings could also be attained through minimisation of staff overtime 
required.  As the ART process would already be incorporated in the workflow 
for a high-risk patient, it is unlikely that Radiation Therapy or Medical Physics 
staff would be required to work outside standard hours, generally paid at 
double time, to complete urgent re-planning.  Based on local data, this could 
result in savings of approximately $800 per patient on staff time alone.  Over 
time, reduction in both staff and resource costs would result in considerable 
savings for a department.   
9.6 During treatment monitoring 
In order to most accurately predict H&N patients that will require ART, it was 
important to recognise appropriate tools to employ in monitoring patients as 
they progress through treatment.  The standard use of three-dimensional 
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IGRT for these patients facilitates the easy implementation of suitable 
monitoring strategies.  To assist in the clinical decision making regarding the 
need to re-plan whist a patient is on treatment, further analysis of the data 
from Chapter 7 was undertaken.  The greatest difference between the patient 
external contours on the planning CT and re-CT in the treatment area was 
measured for all patients who underwent a re-CT.  Patients who had a re-
plan were compared with those who only had a re-CT.  On the ipsilateral side, 
re-planned patients had a significantly greater reduction in external contour 
than those who only had a re-CT (1.83 cm and 1.15 cm respectively, p=0.02).  
On the contralateral side, re-planned patients had a smaller reduction in 
external contour in comparison to the re-CT only group, but was not 
statistically significant (0.73 cm and 1.03 cm respectively).  The smaller 
reduction in contralateral external contour for those patients who were re-
planned was not clinically significant and was most likely related to the small 
number of patients who were re-planned. 
 
The reduction in ipsilateral external contour significantly related to the need 
for a re-plan (p=0.02). (Figure 9. 3)  This demonstrated that change in patient 
external contour is a useful indicator for requirement to re-plan and as such, 
can be employed as a tool to monitor H&N patients as they progress through 
treatment. 
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Figure 9. 3  CT image demonstrating the difference in external contour 
between the planning and CBCT scans on the ipsilateral and contralateral 
side.  Green line indicated the external contour on the planning scan.  Yellow 
line indicated the external contour on the treatment CBCT. 
Image courtesy of PAH Radiation Oncology Department 
9.7 Phase 1 and 2 comparison 
Comparison of the results from the retrospective (Chapters 4 and 5) and 
prospective (Chapters 6 and 7) phases of this work showed a smaller 
number of patients were re-planned in the retrospective study.  The primary 
difference between these phases, excepting the study design itself, was the 
RT technique used.  The majority of patients in the retrospective phase were 
treated with conventional and 3DCRT techniques whereas the prospective 
phase dictated that patients be treated with IMRT, VMAT or Tomotherapy.  
Interestingly, this comparison demonstrates that the modulated techniques, 
the current gold standard, may be more robust to anatomical change than 
conventional techniques.  Despite this, the results of both phases found that 
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pre-treatment size of the largest involved node was a significant factor in the 
identification of patients who are most likely to need ART.  Another 
interesting connection between the two studies was the similarity in findings 
regarding timing of adaptive intervention.  All re-planned patients in both 
studies had virally associated disease, revealing that this subset of patients 
respond at a similar rate regardless of the treatment technique used.  
Conducting both studies has enabled the strength of the main findings to be 
tested, validated and expanded in more detail in order to create a strong, 
well-rounded and evidence based ART strategy that will be of benefit to RT 
departments both in Australia and overseas.  
9.8 Clinical translation of findings 
An important goal of this research was to develop an approach that was 
clinically feasible to implement.  Therefore, it is important to note that a 
change in ART procedure based on these findings has since been instigated 
in my own workplace.  After detailed discussions with senior management 
and H&N Radiation Oncologists, an ART procedure was developed and 
clinically implemented in September 2015.  
 
Figure 9.1 provides a flow chart of the ART procedure.  All patients undergo 
daily pre-treatment CBCT imaging.  The high risk profile (Chapter 6) was 
included in the clinical ART procedure as it identified those patients most 
likely to require adaptive intervention and as such, of most clinical 
significance.  The modified workflow involves alerting key staff groups of high 
risk patients prior to their treatment commencement and the scheduling of a 
re-CT at the time points suggested in Chapter 7: at the commencement of 
week three for patients with NPC and in week four of treatment for OPC 
patients.  Patients who are not identified as part of the high risk group do not 
have any re-CTs pre-scheduled but have their daily CBCTs regularly 
monitored throughout treatment.  With respect to monitoring patient 
anatomical change during treatment our work practice has been altered in 
line with the study findings on external contour change as previously 
described in Chapter 9.  Our practice now includes the creation of two 
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additional external contours on the CBCT, contracted 1cm and 1.5cm from 
the original external contour, for the purpose of monitoring anatomical 
change as patients progress through treatment.  If the difference between 
the patient’s external contour on the CBCT and the planning CT is greater 
than 1.2cm in any region of the treatment area, planning staff should be 
alerted as soon as possible with the view of booking a re-CT.  A review of the 
new workflow and its impact on resources is planned in September 2016.  It 
is hypothesised that there will be a reduction in the number of unnecessary 
re-CTs (i.e. those not leading to a re-plan) as a result of the better 
identification of patients more likely to need ART.  It is anticipated that this 
will lead to more appropriate utilisation of departmental resources and a cost 
benefit to the department as a result of the reduction in re-imaging.  
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Figure 9. 4  Flow chart of clinical ART procedure  
Patient undergoes CT Simulation 
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• N3 stage disease 
• Initial weight 
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• GTV-n >155cc 
HIGH RISK GROUP 
• NPC 
• N2-3 stage disease 
• Initial weight 
>100kg 
• GTV-n >130cc!
HIGH RISK GROUP 
All remaining OPC 
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LOW RISK GROUP 
Re-CT scheduled at 
fraction 15 (week 4 
of treatment) 
Re-CT scheduled at 
fraction 12 (early in 
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No re-CT 
scheduled 
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Pre-scheduled re-CT ! No pre-scheduled re-CT 
Detailed volumetric image 
review 2 fractions prior to 
pre-scheduled re-CT 
Difference in 
external contour 
between 
treatment and 
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>1.2cm 
Difference in 
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between 
treatment and 
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<1.2cm 
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treatment monitoring !Replan !
During treatment 
monitoring 
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planning images 
>1.2cm 
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between 
treatment and 
planning images 
<1.2cm 
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treatment 
monitoring !Replan !
High risk group Low risk group 
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9.9 Limitations 
The primary limitation of this work was that there was no standard protocol 
governing the decision to re-plan.  Re-plans were clinically implemented at 
the discretion of the treating Radiation Oncologist.  As such, the predictive 
factors identified were based on patients that were selected for ART as 
opposed to requiring it.  Consequently, the application of these results must 
be viewed with caution due to the variation that may exist between Radiation 
Oncologists in deciding to re-plan.  Removing the subjectivity involved in the 
re-plan decision-making process and developing standardised re-plan 
'triggers' and a decision-making pathway requires further investigation.  This 
should be coupled with an evaluation of the clinical benefit to the patient of 
re-planning.  Determining a standard decision-making approach will aid in 
improving the robustness of the entire H&N ART process. 
 
Another limitation of this study was that the predictive models and risk 
profiles were generated using data obtained from only a small number of re-
planned patients.  This finding does reflect the Australian clinical scenario 
however may have affected the validity of the results.  A larger prospective 
study is necessary to validate these findings.   
9.10 Future directions 
This body of work has contributed valuable knowledge to the literature 
regarding H&N ART, particularly in response to the recognised need to better 
identify patients who will likely require ART.  It is anticipated that the results 
of this work will be adopted into the clinical practice of other RT centres 
across the state and country.  Multiple centres in Queensland are currently 
investigating the application of this predictive approach in their own centres.  
There is also great potential for future research in the application of this 
predictive approach in international RT departments.  As the reported replan 
percentage in overseas departments is larger than that in Australia, the 
potential impact of the adoption of a predictive approach may also be greater.  
Future directions for further study in this area should include investigation 
into specific dosimetric thresholds and variances, including a clinical decision 
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making pathway, that dictate the need to re-plan.  The aim of this 
investigation would be to remove some of the subjectivity from the current 
decision making process facilitating a more standard approach to this aspect 
of H&N ART.  This subjectivity was a limitation of the current work and 
standardisation of the decision making process will improve the robustness 
of research in the field of H&N ART.  It was not within the scope of this work 
to conduct an economic analysis of the ART method described but 
evaluation of the economic impact should be undertaken in conjunction with 
clinical assessment of outcomes.  Therefore, future study in this area will 
incorporate an evaluation of the economic impact of this predictive ART 
approach.  Additionally, given the demonstrated benefit of predictive 
modelling using logistic regression in this research, application of this 
method to other cancer sites where ART has been identified as being of 
potential benefit, such as lung cancer, could also be the subject of future 
study.   
9.11 Conclusion 
In conclusion, ART is important for selected H&N patients to ensure the 
delivery of the prescribed dose to tumour volumes whilst minimising the dose 
to surrounding OAR in the presence of anatomical and tumour changes.  The 
identification of predictive factors is of vital importance in developing optimal 
processes for ART implementation.  This study developed predictive models 
and risk profiles proposed for clinical implementation to identify OPC or NPC 
patients, before treatment commencement, that are most likely to require 
ART.  This unique prospective approach could facilitate effective 
implementation of ART into radiotherapy departments through forward 
planning and appropriate resource allocation.  Predicting patients more likely 
to need ART in an efficient and judicious manner greatly benefits the 
department and ultimately, the patient. 
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Purpose/Objectives 
Adaptive radiotherapy (ART) can account for the dosimetric impact of 
anatomic and tumour changes throughout the course of chemo-RT for locally 
advanced head and neck cancer (HNC).  However, it is time and resource 
intensive making identification of patients most likely to require ART of vital 
importance.  Logistic regression enables prediction of the risk of events 
occurring and CART analysis is a simple analytic tool that helps determine 
the key variables in a population to design an explanatory model.  This 
makes them attractive tools to use in the setting of HNC ART 
We sought to investigate the utility of logistic regression modeling and 
classification and regression tree (CART) analysis in developing predictive 
models for HNC patients likely to benefit from ART. 
 
Materials/Methods  
Patients with node-positive oropharyngeal squamous cell carcinoma (OPC) 
and nasopharyngeal carcinoma (NPC) treated with curative intent chemo-RT 
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were enrolled prospectively onto the study.  Patients underwent a second 
planning CT scan if the change in external contour between the planning 
scan and daily treatment scan was > 1cm.  The dosimetric impact was 
assessed and a replan generated if target volume coverage was inadequate 
or organs at risk dose exceeded tolerance.  Patient demographics and 
tumour characteristics were recorded and compared between patients who 
were replanned and those that were not.  Univariate and multivariate 
analyses were performed and factors found to be significant for replanning 
included in logistic regression and CART analysis.  To assess the logistic 
regression and CART analysis with larger patient numbers, it was repeated 
on all patients who underwent a second planning scan, making the 
assumption that this scenario always necessitates replanning. 
 
Results 
One hundred and ten patients were enrolled between October 2013 and 
December 2014. The majority were OPC (84.5%), male (91.8%) and were 
predominantly T2 (33.6%) and N2 (80%) stage.  Twenty-one patients 
(19.1%) underwent a second planning scan. and of these 5 (4.9%) patients 
underwent a replan.  Nodal disease stage, pre-treatment size of the largest 
node, diagnosis (p<0.01) and initial weight (categorised in 2 groups) (p<0.07) 
were identified as significant for inclusion in the logistic regression model 
predicting the need to replan.  When the percentage of patients replanned 
was increased, nodal disease stage (p=0.06), pre-treatment size of the 
larges node, diagnosis, initial weight and percentage weight change (p<0.01) 
were identified as significant for inclusion in the logistic regression model.   
 
Conclusion 
Predictive modeling, using logistic regression and CART analysis, can be 
utilised in the identification of OPC or NPC patients more likely to require 
ART.  This could facilitate the efficient implementation of ART resulting in the 
appropriate allocation of institutional resources.  !
 
 
